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Abstract (299 words) 
In preimplantation mouse embryos, signalling and gene regulatory networks cooperate to 
determine lineage segregation, and modulating signalling in vitro allows for stem cell 
populations to be established from these lineages. Fibroblast growth factor (FGF) signalling 
triggers the differentiation of primitive endoderm (PrE) cells fated to contribute to the yolk sac, 
while cells unreceptive to FGF form the epiblast (Epi) that subsequently contributes to the 
embryo proper. In vitro, FGF signalling is required for preimplantation Epi-derived mouse ES 
cells to exit self-renewal. Conversely, in human ES cells and postimplantation Epi-derived mouse 
epiblast stem cells, FGF signalling is instead required for pluripotency maintenance. It remains 
unclear how these divergent outcomes arise, especially as these cells rely on a similar core 
pluripotency gene network. 
This study demonstrates that ectopic expression of the PrE transcription factor Gata6 
destabilises mouse ES cell pluripotency in vitro and upregulates PrE-associated genes 
independently of FGF signalling. As previous studies show that PrE specification is 
compromised in Fgf4-/- embryos, despite initiation of Gata6, this suggests FGF signalling and 
Gata6 cooperatively drive PrE specification in vivo. Characterising Gata6 function determines 
that it directly binds to both up- and downregulated gene targets and potently initiates 
reprogramming in multiple cell types, including human ES cells, suggesting it may also 
antagonise pluripotency in vivo. 
Surprisingly, FGF stimulation negatively affects establishment of the pluripotent human Epi. 
Characterising alternative signalling pathways in the human embryo finds that modulating IGF 
signalling promotes proliferation of the human ICM, and similar to human ES cells, intact 
TGFβ/Nodal signalling is required for pluripotent gene expression in the Epi. Consequently, as 
signalling requirements in the human Epi appear somewhat distinct from both the mouse Epi 
and existing human ES cells, modulating embryo-specific signalling pathways may permit 
derivation of human ES cells that more accurately reflect the pluripotent Epi compartment.  
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Introduction 
 
1. Lineage specification in the preimplantation embryo 
Preimplantation mouse and human embryos exhibit remarkably similar morphology, and 
development at this stage involves a series of cell fate choices as fertilised 1-cell zygotes undergo a 
number of mitotic cell divisions; three rounds of cleavage to form an 8-cell embryo, followed by 
compaction and cavitation to form a blastocyst (reviewed in (Kojima et al. 2014b)). However, 
there are a number of significant distinctions in human development (De Paepe et al. 2014), such 
as a longer temporal period for blastocyst formation, and different timing of major 
zygotic/embryo genome activation, which occurs between the 2- and 4-cell stages in the mouse 
(Hamatani T. 2004) but between the 4- and 8-cell stages in human embryos (Niakan et al. 2010). 
During early embryonic development, cells become gradually restricted in their differentiation 
potential, with cell identity determined by position, polarisation, asymmetric cell division and 
lineage-specific gene expression (Schrode et al. 2014; Chazaud and Yamanaka 2016). A timeline 
of preimplantation development in mouse and human ES cells is shown in Figure A. 
 
The first lineage specification event in the mouse is the segregation of the inner cell mass (ICM) 
and the trophectoderm (TE), with the latter contributing solely to the foetal portion of the 
placenta. This is followed by the specification of the cells within the ICM to either pluripotent 
epiblast (Epi) progenitor cells, which form the embryo proper, or to primitive endoderm (PrE) 
cells, which contribute predominantly to the yolk sac (Gardner et al. 1973; Gardner and Rossant 
1979; Gardner 1985). These contributions were assessed by analysis of mouse postimplantation 
phenotypes, which for ethical reasons cannot be carried out in the human, but it is likely that 
these assignations hold true in a human context. Each lineage is characterised by a network of 
supporting genes, mainly transcription factors, whose role was largely identified through mouse 
mutant phenotypes affecting lineage emergence or maintenance. The present study will focus 
mainly on the emergence of the Epi and PrE lineages within the ICM, rather than on the TE. 
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In the mouse Epi this network is centred on Oct4 (Pou5f1), Sox2 and Nanog, while the PrE 
instead requires an extraembryonic endoderm (ExEn) program, including transcription factors 
Gata6 and Sox17. Both Pou5f1-/- and Nanog-/- embryos fail to form a pluripotent epiblast  
(Chambers et al. ; Nichols et al. 1998; Mitsui et al. 2003), and all cells in the Nanog-/- ICM instead 
express Gata6 (Frankenberg et al. 2011). Sox2-null embryos appear normal until shortly after 
implantation, however this is thought to be due to persistent maternal Sox2 protein (Avilion et 
al. 2003). Both Pou5f1-null or Sox2-null mutant ICM outgrowths only give rise to trophectoderm 
cells (Nichols et al. 1998; Avilion et al. 2003). Although previously thought to have a 
postimplantation ExEn phenotype (Morrisey et al. 1998; Koutsourakis et al. 1999), recent work 
has shown that Gata6-/- embryos fail to form the PrE, and Oct4, Nanog, and Sox2 are instead 
expressed across the ICM (Bessonnard et al. 2014; Schrode et al. 2014). Fewer PrE cells are 
observed in heterozygous Gata6+/- embryos, indicating a threshold of Gata6 expression is 
required for PrE specification. Although Sox17-/- embryos form a PrE layer, PrE cells are 
progressively lost if implantation is delayed in these embryos (Artus et al. 2011), suggesting 
Sox17 is required for PrE maintenance.  
 
These distinct gene expression patterns were confirmed by genome-wide expression analysis 
(Kurimoto et al. 2006; Guo et al. 2010) and provide a useful means of tracking lineage 
specification during preimplantation development, especially in the mouse. Oct4 is expressed in 
all cells within the ICM, and only becomes restricted to the Epi in the late blastocyst (Grabarek et 
al. 2012). Nanog and Gata6 are the earliest markers of the presumptive Epi and PrE, and are 
initially co-expressed before resolving into a mosaic salt-and-pepper pattern in the ICM (Plusa et 
al. 2008). Experiments using PdgfraH2B-GFP reporter mice to mark presumptive PrE cells showed 
that ICM cells initially randomly segregate, with Epi or PrE commitment correlated with Nanog 
or Gata4 upregulation respectively, and cell migration and subsequent apoptosis ensuring that 
cells are correctly located (Plusa et al. 2008). 
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The mechanisms of lineage specification in the human ICM are much less well characterized, 
although some gene expression patterns are shared with the mouse (De Paepe et al. 2014). OCT4 
is initially expressed in all cells before being restricted to the human Epi in the late blastocyst 
(Niakan and Eggan 2013), along with NANOG and SOX2 (Cauffman et al. 2009). Furthermore, 
SOX17 is localized to the PrE, where it overlaps with GATA6 (Niakan and Eggan 2013). 
However, although the TE lineage specifier Cdx2 is expressed from the morula stage in the 
mouse, CDX2 was only detected after cavitation in the human blastocyst, suggesting lineage 
specification mechanisms may not necessarily be conserved between the two species. In contrast, 
cynomolgus monkey embryos exhibit remarkably similar OCT4 and CDX2 expression dynamics 
to those in the human embryo (Nakamura et al. 2016), which may indicate the existence of a 
primate lineage specification mechanism that is distinct from rodents. Intriguingly, single cell 
transcriptomic analysis of cynomolgus monkey (Nakamura et al. 2016) and human embryos 
(Petropoulos et al. 2016) seemingly identifies the TE, Epi and PE emerging concurrently at the 
blastocyst stage, rather than in two sequential steps as in the mouse. Several Epi- and TE-
associated genes are initially co-expressed in the human embryo before being restricted to their 
specific lineages (Petropoulos et al. 2016). This may reflect greater plasticity during early primate 
development, and both inner and outer cells of blastocysts disaggregated at embryonic day 5 (E5) 
are capable of forming a blastocyst with both an ICM and TE (De Paepe et al. 2013). Further 
analysis of protein expression patterns during development will be crucial to support these 
conclusions, especially with regards to novel lineage markers that are highly enriched in the 
human embryo (such as ARGFX and KLF17 in the Epi, FOXA2 in the PE, and GATA2 and 
GATA3 in the TE, (Blakeley et al. 2015; Petropoulos et al. 2016)). 
 
2. Signalling in the early embryo – defining the Epi and PrE 
Extracellular signalling has been linked to Epi and PrE specification in the mouse, but it is 
unclear to what extent this is conserved in the human. In the mouse embryo, fibroblast growth 
factor (FGF) signalling, and consequent activation of the mitogen-activated protein kinase 
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(MAPK) pathway, is required to facilitate the segregation of Epi and PrE lineages (Lanner and 
Rossant 2010). A complementary receptor-ligand relationship has been proposed, where the 
FGF receptor Fgfr2 is thought to be more highly enriched in PrE cells, while EPI cells secrete an 
FGF ligand, Fgf4, (Rappolee et al. 1994; Goldin and Papaioannou 2003; Guo et al. 2010). In 
addition, mutations in genes coding for FGF signalling pathway components result in defects in 
PrE formation, phenocopying the effects seen with mutations in various lineage specifiers. Fgfr-/- 
and Fgf4-/- mutant embryos fail to form a PrE layer (Feldman et al. 1995; Arman et al. 1998), as 
do Grb2-/- mutant embryos, where loss of the Grb2 adaptor protein affects FGF signal 
transduction (Cheng et al. 1998).  
 
In addition to morphological defects, disrupting FGF signalling also affects gene expression 
patterns within the ICM. Gata6 expression is lost in the Grb2-/- E3.5 ICM, where all cells become 
Nanog-expressing epiblast progenitors (Chazaud et al. 2006). Inhibiting FGF receptors or the 
MAPK Mek also increases the proportion of Nanog-expressing cells within the ICM (Nichols et 
al. 2009; Yamanaka et al. 2010), suggesting that FGF signalling primarily functions via the Raf-
Mek-Erk pathway. Both Mek1 and Erk2 mutants have an embryonic lethal phenotype in mice 
(Giroux et al. 1999; Hatano et al. 2003) suggesting a key and distinct role for these kinases during 
early development. Conversely, treatment with FGF ligands alone or coupled with the FGF 
receptor binding facilitator heparin resulted in downregulation of Nanog expression and 
conversion to Gata6-positive PrE progenitors (Yamanaka et al. 2010).  
 
However, it is unclear how FGF signalling interacts with either the pluripotency or the ExEn 
gene regulatory networks in the mouse embryo. Recent studies show that Gata6 is initiated in 
Fgf4-/- mutant embryos at E2.0, but subsequent activation of PrE factors Gata4 and Sox17 is 
compromised (Kang et al. 2013). Although it was previously reported that Gata6 is not expressed 
in Grb2-/- embryos at E3.5 (Chazaud et al. 2006), by this time Gata6 expression has diminished in 
Fgf4-/- embryos, making it likely that Gata6 is also initiated but not maintained in Grb2-/- 
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embryos. Although ectopic expression of Gata6 in Grb2-/- embryos can rescue the PrE 
differentiation defect (Wang et al. 2011), exogenous FGF signalling is not sufficient to drive 
Gata4 and Sox17 expression in Gata6-/- embryos (Schrode et al. 2014). Furthermore, modulating 
FGF signalling at E3.5, after Gata6 or Nanog were expressed, did not affect lineage specification.  
This seemingly suggests that Gata6 lies downstream of FGF signalling to drive a PrE fate. 
 
The signalling pathways responsible for lineage specification in the human ICM are less well 
characterised, despite conservation of lineage-specific genes between mouse and human 
embryos. Curiously, inhibiting FGF signalling in human embryos (Kuijk et al. 2012; Roode et al. 
2012) has no effect on either PrE or Epi formation in the human blastocyst, and gene expression 
patterns are unchanged. However, Nodal- or Activin-driven TGFβ signalling has been shown to 
have a role in maintaining pluripotency in vitro, which will be discussed below, and inhibiting 
TGFβ/Nodal in the human embryo affects the expression of NANOG (Blakeley et al. 2015).  
 
Overall, gene networks and signalling pathways appear to intersect in order to determine and 
maintain lineage fate in both the mouse and the human embryo. Consequently, appropriately 
modulating signalling pathways has enabled the establishment of cell lines in vitro that retain the 
characteristics of their embryonic cell type of origin. 
 
3. Capturing pluripotency in vitro 
A number of observations provided the foundations for the derivation and subsequent 
appreciation of embryonic stem cells. It was noted that scrotal tumours spontaneously arose in 
129 strain mice (Stevens and Little 1954; Stevens 1967), and that these teratomas were comprised 
of a mixture of several different cell types. These masses could be transplanted to colonise other 
sites, and were thus designated as teratocarcinomas, with the hypothesis that the constituent 
embryonal carcinoma (EC) cells were a type of undifferentiated stem cell (Kleinsmith and Pierce 
1964). Supporting this, single EC cells were shown to be sufficient to generate all the divergent 
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tissues observed in teratocarcinomas (Kleinsmith and Pierce 1964; Martin and Evans 1974), and 
were thus pluripotent. Cells isolated from the mouse ICM were shown to have a similar antigen 
expression pattern to mouse EC cells, suggesting they too may be pluripotent. Consequently, 
conditions used to culture mouse EC cells were applied to attempt to generate stable cell lines 
from mouse preimplantation embryos. 
 
Deriving mouse embryonic stem (ES) cells 
The first stable mouse ES cells were derived from 129 strain mice in two concurrent studies. 
Diapause-induced blastocysts were plated intact in microdrops of serum-containing medium 
and colonies reminiscent of EC cells picked and passaged to derive a stable cell line (Evans and 
Kaufman 1981). The resulting cells were karyotypically normal and contributed to 
teratocarcinomas when injected subcutaneously into recipient adult mice. In the alternative 
study, isolated ICMs from normal blastocysts were plated onto a STO feeder layer in serum-
containing feeder-conditioned medium (Martin 1981). Again, EC-like colonies emerged and 
could be maintained, and gave rise to teratocarcinomas in vivo, and to multiple differentiated 
tissues in EB assays in vitro.  
 
The term “embryonic stem cell” was coined to distinguish these cells from their EC counterparts 
and to reflect their embryonic origin (Martin 1981). Subsequent studies showed that mouse ES 
cells successfully contributed to chimaeras (Bradley et al. 1984), predominantly to foetal and 
extraembryonic mesoderm tissue, and with only a low frequency to the TE and PrE (Beddington 
and Robertson 1989). Mouse ES cells depend on a gene regulatory network surrounding the core 
transcription factors Oct4 (Pou5f1), Sox2, and Nanog (Boyer et al. 2005; Loh et al. 2006; Chen et 
al. 2008), similar to the Epi compartment from which they were initially derived. Additional 
transcription factors such as Esrrb and Klf4 are also regulated by and reinforce the core 
pluripotency factors (Ivanova et al. 2006; van den Berg et al. 2008; Zhang et al. 2008; Hall et al. 
2009; Niwa et al. 2009; Festuccia et al. 2012). Mouse ES cells that lack Pou5f1 or Sox2 lose 
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expression of pluripotency genes and differentiate primarily into trophectoderm stem (TS) cells 
(Niwa et al. 2000; Avilion et al. 2003; Mitsui et al. 2003; Ivanova et al. 2006; Masui et al. 2007). 
Although, Nanog mutant mES cells have been established by gene deletion in vitro they can only 
be maintained if leukaemia inhibitory factor (LIF) signalling is intact (Chambers et al. 2007). 
 
LIF signalling was the first pathway identified as required for pluripotency maintenance. Briefly 
described as the differentiation inhibitory activity (DIA) factor that was secreted by MEFs to 
maintain mouse ES cells (Smith et al. 1988; Williams et al. 1988; Stewart et al. 1992), exogenous 
LIF was shown to replace the requirement for a MEF supportive layer in ES cell maintenance and 
derivation (Nichols et al. 1990). LIF maintains pluripotency via activation of JAK/STAT 
signalling, specifically Stat3, which triggers downstream gene expression to block differentiation 
towards mesoderm and endoderm lineages (Niwa et al. 1998; Bourillot et al. 2009). Serum and 
LIF are still routinely used to maintain ES cells in culture. In addition, bone morphogenetic 
protein (BMP) signalling can substitute for serum in mouse ES cell maintenance, acting via 
Smad and Id proteins to cooperate with LIF to maintain pluripotency (Ying et al. 2003). 
 
Consistent with the mouse embryo, inhibiting FGF/Erk signalling in mouse ES cells also 
maintains pluripotency (Burdon et al. 1999; Kunath et al. 2007; Stavridis et al. 2007). Self-
renewing pluripotent ES cells can be derived from Grb2-/- mouse embryos, but are refractory to 
endoderm differentiation in vitro, which can be restored by introducing a Sos1-Grb2 fusion to 
transduce FGF signalling (Cheng et al. 1998; Hamazaki et al. 2006; Wang et al. 2011; Findlay et 
al. 2013). Furthermore, addition of FGF4 to Pou5f1-/- ICM outgrowths which do not express Fgf4, 
promotes proliferation of TS cells (Nichols et al. 1998), further indicating that FGF4 is 
dispensable for ES cell maintenance. Conversely, constitutive active Mek results in Nanog 
repression in mouse ES cells (Hamazaki et al. 2006), indicating that FGF seemingly exercises the 
same dynamics in mouse ES cells as it does during Epi and PrE segregation in the embryo. 
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Although ES cells had been successfully derived from 129-related mouse strains, several other 
strains remained refractory to ES cell derivation (Gardner and Brook 1997; Blair et al. 2011). Cell 
lines from some these alternative strains could only be generated by hormonally inducing 
diapause to mimic in vivo embryonic delay, and even then cells were only derived at very low 
efficiencies. Consequently, it seemed plausible that confounding factors in culture were 
disrupting the pluripotency network, perhaps via FGF/Erk signalling activation, which was 
demonstrably detrimental. As conditions for serum- and feeder-free defined cultures had now 
been established (Ying et al. 2003), but neither LIF nor BMP blocked Erk activation in vitro, it 
was speculated that perhaps directly modulating FGF/Erk signalling would enable improved 
propagation of mouse ES cells (Ying et al. 2008). 
 
Culture in 2i and LIF – “naïve” mouse ES cells 
The addition of Mek and Gsk3β inhibitors together with LIF (2i+LIF, originally 3i+LIF) allowed 
mouse ES cells to be propagated in defined medium in the absence of BMP, serum or a MEF 
supportive layer (Ying et al. 2008; Nichols et al. 2009). Interestingly, Stat3-null mouse ES cells 
can be derived and maintained in 3i conditions, though they differentiate rapidly when returned 
to conventional culture (Ying et al. 2008), indicating that the inhibitors bypass a requirement for 
Stat3 activation. Gsk3β inhibition prevents phosphorylation (and subsequent degradation) of 
β-Catenin, which although not essential to maintain pluripotency provides additional resistance 
to differentiation (Lyashenko et al. 2011; Wray et al. 2011). Mouse ES cells lacking the 
transcriptional repressor Tcf3 do not respond to Gsk3β  inhibition and upregulate Esrrb and 
Nanog, suggesting that Gsk3β inhibition alleviates repression of Tcf3 gene targets essential for 
pluripotency differentiation (Wray et al. 2011; Martello et al. 2013). 
 
Remarkably, 2i+LIF conditions overcame the barriers to derivation previously observed, 
allowing stable ES cells to be established from alternative mouse strains, and from rat embryos 
(Buehr et al. 2008; Nichols et al. 2009). ES cells in 2i+LIF are thought to represent a “ground 
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state” of pluripotency, and have been shown to more closely resemble cells in the mouse 
preimplantation ICM, as compared to cells in classical serum and LIF culture conditions which 
correlate with later preimplantation epiblast stages (Boroviak et al. 2014). Cells in 2i+LIF also 
exhibited less heterogeneity compared to their serum and LIF counterparts. Altogether, this 
strongly suggests that current ES cell culture conditions appropriately capture the mouse 
pluripotent state. However, it is unclear whether the same is true in a human context. 
 
Deriving human ES cells 
The first human ES-like cells were isolated from human embryos that were plated and allowed to 
hatch onto a human oviduct epithelial feeder layer, in the presence of human serum and LIF 
(Bongso et al. 1994). After hatching, the ICM clumps that attached to the monolayer were 
disaggregated and sub-cultured in an attempt to maintain a stable self-renewing line. Although 
cells retained stem cell-like morphology, normal karyotype and stained positive for alkaline 
phosphatase, they could not be maintained for more than two passages (Bongso et al. 1994). 
 
However, similar experiments performed in non-human primates were more successful. 
Immunosurgery was carried out on rhesus monkey or marmoset blastocysts to remove the 
trophectoderm, allowing the intact ICM to be plated onto a MEF layer and cultured in serum 
and human LIF (Thomson et al. 1995; Thomson et al. 1996). The resulting cell lines stained 
positive for alkaline phosphatase and expressed cell-surface markers characteristic of human EC 
cells such as SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81, which were lost following 
differentiation. Furthermore, cells injected into immunodeficient SCID mice (Thomson et al. 
1995) or aggregated into embryoid bodies (Thomson et al. 1996) differentiated into all 3 
embryonic germ layers, indicating that these cells retained the pluripotent properties of the ICM. 
These primate ES cell lines could be maintained for multiple passages, and remained 
undifferentiated in the presence of MEF layers, but differentiated or died in their absence despite 
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the presence of human LIF. Therefore, although human LIF was added during derivation, it was 
dispensed with for routine culture.  
 
The work in non-human primates refined the techniques that enabled successful derivation of ES 
cells from human embryos. Human ICMs isolated in a similar fashion and plated onto a MEF 
layer in the presence of serum gave rise to the first stable ES cell lines (H1, H7, H9, H13, H14,) 
that could be propagated for multiple passages and had a normal karyotype (Thomson et al. 
1998). These cells also expressed alkaline phosphatase and pluripotency cell-surface markers, and 
formed teratomas when injected into SCID mice. Similar results were observed in a subsequent 
study (Reubinoff et al. 2000), which also demonstrated that although LIF was initially used 
during cell line establishment, it had no effect on the growth or differentiation of established 
cultures. Consequently, although human ES cells expressed OCT4 (Reubinoff et al. 2000) and 
thus likely relied on a similar pluripotency gene network to mouse ES cells, the signalling 
pathways involved were possibly distinct.  A number of human ES cell lines have subsequently 
been derived (Mitalipova et al. 2003; Cowan et al. 2004; Suemori et al. 2006; Aflatoonian et al. 
2010), though the H1 and H9 lines are predominantly used in human ES cell studies (Loser et al. 
2010; Kobold et al. 2015).  
 
Culture in defined conditions 
Although culture conditions using serum and MEF layers had enabled successful human ES cell 
derivation, this again introduced potential issues with batch-to-batch variability and exposure to 
undefined factors with potentially undesirable effects. In addition, a number of studies indicated 
that in contrast to mouse ES cells, LIF was not sufficient to support human ES cell pluripotency 
in the absence of a MEF layer, and neither was activation of downstream STAT3 (Thomson et al. 
1998; Reubinoff et al. 2000; Daheron et al. 2004; Humphrey et al. 2004). Consequently, 
alternative signalling pathways would have to be modulated to support human ES cell 
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maintenance in serum- and feeder-free conditions. A comparison of signalling pathways in 
mouse and human ES cells is shown in Figure B. 
 
FGF signalling emerged as a putative pathway of interest in experiments to clonally culture 
human ES cells (Amit et al. 2000). One caveat of the original derivation experiments was the 
passaging of ICM clumps during derivation, rather than clonal expansion from single cells, as 
despite the homogenous appearance of the resulting cultures there remained the possibility for 
heterogeneity. However, subsequent experiments demonstrated that H9 ES cells lines could be 
clonally expanded without loss of pluripotency, though at a lower cloning efficiency than mouse 
ES cells (Amit et al. 2000). Clonal lines retained a normal karyotype, cell surface marker 
expression and contributed to teratomas as before. Interestingly, using knockout serum 
replacement (KOSR) (Price et al. 1998) in place of serum greatly increased cloning efficiency. 
Furthermore, addition of 4 ng/ml FGF2 to the culture medium resulted in tighter colony 
morphology, and was required for continuous undifferentiated proliferation in serum-free media 
(Amit et al. 2000), suggesting a link to pluripotency maintenance. However, even in the presence 
of FGF human ES cells were still lost to differentiation in the absence of the MEF layer. 
 
Interestingly, human ES cell lines could be maintained on the basement membrane substrates 
Matrigel and laminin in MEF-conditioned medium (MEF-CM) supplemented with 4 ng/ml of 
FGF2 (Xu et al. 2001). This suggested that the missing component was secreted by the MEF 
layer, rather than provided by cell-cell contact. Human ES cells in unconditioned medium alone 
were subject to high levels of BMP signal-inducing activity, which was diminished in MEF-CM 
(Xu et al. 2005). As BMP signalling had been linked to human ES cell differentiation (Xu et al. 
2002; Pera et al. 2004), this likely partially explained why MEF-CM was required for 
pluripotency maintenance. However, MEF-conditioned medium could be dispensed with 
entirely either by adding the BMP antagonist Noggin (500 ng/ml) alongside FGF2 (40 ng/ml), or 
increasing the concentration of FGF2 to 100 ng/ml in unconditioned medium (Xu et al. 2005).  
		 26 
  
		 27 
Consequently, one function of FGF appeared to be to antagonise the differentiation promoting 
effects of BMP signalling.  
 
FGF is present in the majority of human ES cell culture media, if not overtly via addition of 
exogenous ligand, then by culture on MEF layers or in MEF-CM. FGF/Erk inhibition in existing 
human ES cells affects NANOG expression and promotes neural differentiation (Greber et al. 
2010; Greber et al. 2011), consistent with the requirement for FGF to maintain pluripotency. 
However, as discussed above, Erk inhibition in the human embryo has neither a positive or 
negative effect on the epiblast compartment (Kuijk et al. 2012; Roode et al. 2012), suggesting that 
the human epiblast may have distinct downstream signalling requirements.  
 
Core components of the TGFβ/Activin/Nodal signalling pathway have also been shown to be 
expressed in human ES cells, including the ligand Nodal and the receptors ALK4 and ACVR2B 
(Vallier et al. 2004). Human ES cells overexpressing the TGFβ ligand Nodal remained 
undifferentiated in MEF-CM without FGF2 or serum, and maintained SSEA-4 expression. 
Furthermore, MEF-CM was also shown to contain Activin A protein, and Activin A transcripts 
were detected in MEF cells (Beattie et al. 2005; Vallier et al. 2005), indicating that MEF-CM is 
also a source of TGFβ pathway stimulation. Human ES cells cultured in the presence of the 
TGFβ/Activin inhibitors follistatin or SB-431542 no longer expressed TRA-1-60, OCT4 or 
NANOG, while media supplemented with 50 ng/ml Activin A was sufficient to maintain 
pluripotency (Beattie et al. 2005; James et al. 2005; Vallier et al. 2005). 
 
Altogether, Nodal and Activin were found to be interchangeable and both synergised with FGF 
in otherwise chemically defined medium to maintain human ES pluripotency (Vallier et al. 
2005), as did the ligand TGFβ1 (Amit et al. 2004). Activin/Nodal signalling via SMAD2/3 
signalling has since been shown to regulate pluripotency gene expression in human ES and iPS 
cells, binding directly to the NANOG promoter, as well as reinforcing expression of Nodal 
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signalling components (Besser 2004; James et al. 2005; Vallier et al. 2005; Vallier et al. 2009; 
Brown et al. 2011). Consequently, the FGF and TGFβ/Activin/Nodal signalling pathways form 
the cornerstone of classical human ES cell culture conditions, including the commonly used 
defined medium mTeSR™1 (Ludwig et al. 2006) and its further condensed derivative TeSR™-E8™ 
(Chen et al. 2011). A summary of selected media compositions is provided in Table 1. 
 
However, it has been suggested that FGF only indirectly promotes human ES cell pluripotency, 
instead stimulating either the supportive MEF layer (Greber et al. 2007), or fibroblast-like cells 
differentiated from human ES cells themselves (Bendall et al. 2007), to secrete factors that 
subsequently promote pluripotency. Several members of the insulin-like growth factor (IGF) 
family have been detected in MEF-CM (Bendall et al. 2007), and IGF2 has been hypothesized to 
cooperate with FGF to maintain human ES cell pluripotency, functioning via the IGF1 receptor, 
IGF1R (Bendall et al. 2007; Wang et al. 2007). Addition of an IGF1R-blocking antibody to 
human ES cell cultures impeded the expansion of cells expressing the pluripotency-associated 
marker SSEA3 (Bendall et al. 2007), which could not be rescued by supplementation with 
exogenous FGF2. Furthermore, decreased levels of phosphorylated Akt were observed following 
IGF1R blocking (Bendall et al. 2007). Briefly, binding of insulin or IGF ligands to insulin or IGF 
receptors leads to phosphorylation of receptor substrates IRS1 and IRS2, which in turn 
phosphorylate and activate phosphoinositide 3-kinase (PI3K) (reviewed in (Siddle 2011)).  
 
PI3K phosphorylates the membrane-bound phospholipid PIP2 to generate active PIP3, which 
then activates a kinase cascade via phosphoinositide-dependent kinase-1 (PDK1) and its 
substrates Akt and atypical protein kinase Cs (aPKCs). Downstream Akt substrates include 
Gsk3β, whose links to mouse ES cell maintenance are discussed above, as well as factors involved 
in apoptosis and protein synthesis (Siddle 2011). However, constitutive Akt expression 
maintains mouse and non-human primate ES cell pluripotency independently of Wnt/β-Catenin 
signalling (Watanabe et al. 2006), suggesting that Akt-mediated negative regulation of Gsk3β is  
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not the sole mechanism of promoting ES cell maintenance. Interestingly, PI3K/Akt signalling 
can also be activated by FGF (reviewed in (Ornitz and Itoh 2015)), suggesting that FGF also may 
function via Erk-independent pathways to promote ES cell maintenance.  Furthermore, the Grb2 
adaptor protein linked to Ras/MAPK signalling can also be activated by insulin receptor 
substrate Shc (Siddle 2011), suggesting potential crosstalk between these two pathways. 
Altogether, this indicates that additional pathways may be relevant in human ES cell 
maintenance. 
 
Searching for the human naïve state 
Similar to the mouse, human ES cells require OCT4, NANOG and SOX2 to maintain 
pluripotency (Wang et al. 2012). Furthermore, induction of c-MYC and the pluripotency factors, 
OCT4, SOX2 and KLF4 in ES cell culture conditions is also sufficient to reprogram human 
fibroblasts and other somatic cells to iPS cells (Takahashi and Yamanaka 2006; Yu et al. 2007; 
Park et al. 2008). However, human and mouse ES cells have distinct molecular signatures (Sato et 
al. 2004), and human ES cells lack the expression of pluripotency factors associated with the 
mouse preimplantation Epi such as TBX3 and DAX1, instead expressing the mouse 
postimplantation marker OTX2 (Loh et al. 2015). Consequently, classical human ES cells are 
thought to instead represent a later stage of development than their mouse ES cell counterparts, 
even though both are derived from the preimplantation Epi. 
 
This hypothesis is seemingly supported by the existence of mouse epiblast stem cells (EpiSCs), 
which are derived from the postimplantation mouse Epi (Brons et al. 2007; Tesar et al. 2007). 
Human ES cell derivation conditions were tested on pre- and postimplantation mouse embryos, 
and while the preimplantation ICM underwent rapid differentiation, postimplantation Epi layers 
formed compact colonies of cells expressing Oct4 and Nanog (Brons et al. 2007). EpiSCs grow in 
flat epithelial-like monolayers and rely on FGF and Activin/Nodal signalling rather than LIF to 
maintain pluripotency (Brons et al. 2007; Tesar et al. 2007), similar to human ES cells and 
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distinct from mouse ES cells. Furthermore, with the exception of Nanog, EpiSCs do not express 
naïve pluripotency markers, and Oct4 expression in EpiSCs is regulated by the proximal 
enhancer shown to be required for postimplantation, rather than preimplantation, specific 
expression in the mouse embryo (Tesar et al. 2007; Han et al. 2010). Although EpiSCs have been 
successfully derived from a range of developmental stages from E5.5 up to E8.5 (Kojima et al. 
2014a), and even from E3.5 preimplantation mouse embryos (Najm et al. 2011), they exhibit a 
common transcriptomic identity corresponding to the anterior primitive streak (Kojima et al. 
2014a). Both human ES cells and mouse EpiSCs do not incorporate into mouse blastocysts to 
form chimeras (Huang et al. 2012; Masaki et al. 2015), though EpiSCs can contribute to post-
implantation embryos (Huang et al. 2012; Kojima et al. 2014a) and human ES cells have recently 
been shown to contribute to later stage mouse embryos (Mascetti and Pedersen 2016). 
 
Interestingly, if iPS cell reprogramming with the Yamanaka factors is performed in EpiSC 
culture conditions, the resulting cells exhibit EpiSC morphology and characteristics (Han et al. 
2011), indicating the culture environment does have a significant impact on cell identity. When 
EpiSCs are cultured in the 2i+LIF conditions that would support naïve mouse ES cells, a very 
small proportion of cells revert to an earlier stem cell identity, but ectopic expression of mouse 
ES cell genes such as Klf2, Klf4 or Nr5a2 is required to increase this in a meaningful way (Guo et 
al. 2009; Hall et al. 2009; Hanna et al. 2010). Nevertheless, several putative human ES cell culture 
conditions have recently been investigated, in an attempt to derive stem cells that more closely 
resemble “ground state” naïve mouse ES cells (Ying et al. 2008).  
 
Studies attempting to derive naïve human ES cells utilise a combination of growth factors and 
inhibitors to modulate various signalling pathways (Hanna et al. 2010; Chan et al. 2013; Gafni et 
al. 2013; Takashima et al. 2014; Theunissen et al. 2014; Valamehr et al. 2014; Ware et al. 2014), as 
well as ectopic transgene expression of KLF2 and NANOG (Takashima et al. 2014; Theunissen et 
al. 2014). A summary of selected media formulations is shown in Table 2. Putative conditions  
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often include the Mek and Gsk3β inhibitors used in mouse 2i+LIF media, however culture in 
2i+LIF alone is unable to support the self-renewal of human ES cells (Hanna et al. 2010). In 
contrast, neither LIF nor constitutive STAT3 expression is sufficient to maintain pluripotency of 
existing human ES cells (Thomson et al. 1998; Humphrey et al. 2004). This may impact the 
conclusions drawn from naïve protocols in human ES cells, as the benchmark against which 
these cells are assessed relies heavily on conclusions drawn from mouse ground state 
pluripotency. Transcription factors such as KLF2 and ESRRB are not appreciably expressed in 
the human Epi (Blakeley et al. 2015), though both are thought to be essential for maintaining 
ground state pluripotency in the mouse (Martello et al. 2013; Yeo et al. 2014). This complicates 
the use of mouse naïve factors either as a driving force towards or as an indicator of a more naïve 
human pluripotent state. Despite this, gene expression patterns in naïve human ES cells are more 
similar to the human Epi than to naïve mouse ES cells (Huang et al. 2014), suggesting that 
perhaps these conditions may inadvertently intersect with human pluripotency maintenance 
networks. Some studies also demonstrate a switch from OCT4 expression from the distal 
enhancer in naïve human ES cells, rather than the proximal enhancer active in primed cells 
(Gafni et al. 2013; Takashima et al. 2014; Theunissen et al. 2014; Ware et al. 2014), which is also 
based on naïve pluripotency dynamics in the mouse (Yeom et al. 1996; Choi et al. 2016). 
However, this assumes similar modes of upstream regulation of the OCT4 enhancer and 
promoter region in the human embryo, and although the sequences are conserved in the mouse 
and human genes (Nordhoff et al. 2001), there is currently no further data to support this 
hypothesis. 
 
Further analysis directly in human embryos may reveal human-specific signalling networks that 
could be modulated, rather than relying on those characterised in rodent models. In addition, 
recent gene expression studies in the human embryo may also provide new benchmarks for 
assessing the relationship of naïve conditions to in vivo pluripotency, such as human Epi-specific 
transcription factors like KLF17 (Blakeley et al. 2015) or additional molecular criteria such as 
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transposon signatures (Theunissen et al. 2016). Indeed, upregulated KLF17 transcript or KLF17 
protein expression can be detected in certain naïve human ES cell cultures (Blakeley et al. 2015; 
Guo et al. 2016; Collier et al. 2017). Increased genome-wide DNA demethylation following 
adaptation to naïve culture conditions (Gafni et al. 2013; Guo et al. 2016; Theunissen et al. 2016) 
also correlates with the hypomethylated status observed in the human ICM (Guo et al. 2014; 
Smith et al. 2014), which also happens to characterize naïve pluripotency in mouse ES cells 
(Leitch et al. 2013). 
 
Nevertheless, human ES cells remain somewhat distinct from the human Epi (Yan et al. 2013; 
Blakeley et al. 2015), suggesting that current in vitro culture conditions, naïve or otherwise, do 
not fully reflect the conditions required for pluripotency maintenance in vivo. Although naïve 
human ES cells are more similar to the human embryo than their primed counterparts (Yan et al. 
2013; Blakeley et al. 2015), they do not necessarily completely resemble a specific developmental 
stage. This is in contrast to the mouse system where mouse naïve or primed ES cells, and mouse 
EpiSCs show similar gene expression profiles to, and cluster with, embryonic cell types (Boroviak 
et al. 2014; Boroviak et al. 2015). Additionally, certain cell surface markers have recently been 
shown to accurately delineate naïve human ES cell populations, but do not necessarily exhibit an 
Epi-restricted expression pattern in the human embryo (Collier et al. 2017). It is likely that 
further refinement is required to derive human ES cells that more closely resemble the human 
embryo.  Nevertheless, given that naïve human cells adopt embryo-associated characteristics, 
such as for example, global demethylation, studying the transition between primed and naïve 
cells presents a useful model to better understand how these processes occur. Furthermore, the 
various naïve cells share a core transcriptional network despite their different culture systems 
(Huang et al. 2014). It would be interesting to further analyse these genes to determine if they 
lend insight into the fundamental underpinnings of the human pluripotent state. Characteristics 
of mouse ES cells and EpiSCs compared to conventional and naïve human ES cells are shown in 
Table 3. 
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Summary 
Signalling and gene regulatory networks cooperate to determine lineage segregation in the 
embryo, and modulating signalling in vitro allows for stem cell populations to be established 
from these lineages. FGF signalling in particular destabilises pluripotency in the Epi or in mouse 
ES cells, but promotes the PrE lineage in the mouse preimplantation embryo. Precisely how FGF 
functions to drive these alternative outcomes is only just beginning to be elucidated. Curiously, 
FGF is instead routinely used to maintain pluripotency in human ES cells, and in EpiSCs derived 
from post-implantation mouse Epi. Human ES cells generally more closely resemble EpiSCs than 
mouse ES cells in their morphology and signalling requirements, despite being derived from the 
preimplantation embryo. This would seemingly suggest either a species-specific discrepancy 
related to FGF signalling in the preimplantation embryo, or differences in the downstream 
effectors of FGF in these alternative contexts.  
 
Consequently, the work described in this study aimed to address two main areas. Firstly, to 
interrogate the downstream mechanics of FGF/Erk signalling in mouse ES cells, where the effect 
of FGF signalling correlates with that in the embryo. Determining how signalling functions to 
destabilise the existing pluripotency network could provide insights into how FGF preferentially 
promotes a PrE identity during lineage specification in the ICM. An Erk2-Venus fluorescent 
reporter mouse ES cell line was used to investigate Erk localisation dynamics in response to FGF 
stimulation, and how this is related to lineage segregation in vivo and ES cell differentiation in 
vitro. In addition, a number of transgenic inducible mouse ES cells were characterised in order to 
investigate how lineage-specifying transcription factors integrate with FGF signalling to disrupt 
pluripotency regulation.  
 
The second aim was to investigate FGF signalling more thoroughly in the human ICM, making 
use of access to donated human embryos that were surplus to family building, in an attempt to 
reconcile the divergent outcomes of FGF/Erk inhibition in human ES cells compared to the 
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human embryo. Finally, a recently acquired single cell transcriptomics dataset was explored to 
characterise human Epi-specific gene expression and more comprehensively determine 
conditions that would best support pluripotency maintenance. 
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Materials and Methods 
1. Mouse cell culture 
1.1. Routine maintenance of mouse ES cells, XEN cells and neural stem cells 
Mouse ES cells were generally maintained on mouse embryonic fibroblast (MEF)-coated pre-
gelatinized tissue culture plates (Corning) in serum and 10 ng/ml of LIF (KSR+LIF). 
Recombinant LIF was produced by Marko Hyvonen (University of Cambridge, Department of 
Biochemistry). MEF plates were prepared 24 hours in advance using MEF medium. Full KSR 
and MEF media compositions are listed in the Reagents section below. Mouse ES ells were 
passaged every 2-3 days with 0.05% Trypsin-EDTA (Sigma).  
 
For experiments carried out in the absence of exogenous FGF, mouse ES cells were cultured in 
serum-free neurobasal medium (NDiff 227, Cellartis/Takara Bio) supplemented with 1 µM of 
Erk inhibitor PD0325901 (Tocris), 3 µM of Gsk3 inhibitor CHIR99021 (Axon), and 10 ng/ml of 
LIF (2i+LIF conditions, (Ying et al. 2008). Cells were cultured on gelatine-coated tissue culture 
plates in 2i+LIF for at least 3 passages prior to any experimental setup.  
 
ZHBTc4 Oct4 conditional knockout mouse ES cells (Niwa et al. 2000) were routinely cultured as 
above, and treated with 1 mg/mL of doxycycline as required to generate Oct4-null cells. ZHBTc4 
mouse ES cell lines were kindly supplied by Austin Smith. 
 
Mouse embryo-derived XEN (eXEN) cells, and transcription factor-induced XEN (iXEN) cells 
generated in this study, were routinely maintained on gelatine-coated tissue culture plates in 
XEN maintenance media (adapted from (Kunath et al. 2005). The full XEN media composition 
is listed in the Reagents section below. Mouse eXEN cells were kindly supplied by Janet Rossant. 
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The NS5 neural stem cell line (Conti et al. 2005) was cultured in Euromed-N media (EuroClone) 
supplemented with L-glutamine, laminin, N2, BSA, FGF2 and EGF (R&D or Life Technologies). 
Cells were routinely passaged using Accutase (Life Technologies). NS5 cells were kindly supplied 
by Zachary Gaber and Francois Guillemot. 
 
Mouse cells were frozen down in a minimal volume of 10% DMSO in serum as standard. When 
thawed, cells were resuspended in the relevant culture media and washed twice to remove traces 
of freezing medium (cells were pelleted by centrifugation, supernatant was aspirated and 
replaced with fresh media) before plating for culture.  
 
1.2. Generation of transgenic mouse ES cell lines 
Erk2-Venus mouse ES cell lines were generated in collaboration with Russell Ernst. R1 mouse ES 
cells (Nagy et al. 1993) were electroporated with a pCAGGs vector containing a C-terminal 
targeting construct incorporating part of Exon 8 of the Erk2 allele followed by an in-frame Venus 
tag, as well as a hygromycin resistance sequence separated from the Venus sequence by an T2A 
peptide. Successfully targeted ES cell colonies were selected using hygromycin (50-100 μg/mL). 
 
Doxycycline-inducible cell lines were generated by Lily Cho and Kathy Niakan using KH2 mouse 
ES cells (Beard et al. 2006), previously modified to include an M2-rtTA tetracycline-responsive 
transactivator under the control of the Rosa26 promoter, plus a tetracycline operator minimal 
promoter incorporated into the Col1a locus (Hochedlinger et al. 2005; Beard et al. 2006). Gata4, 
Gata6, Hnf4a, Foxa3, Sox7 and Sox17 cDNA sequences were PCR-amplified from XEN cell lines 
and integrated into a pgkATGfrt vector that also conferred hygromycin resistance, then co-
electroporated into KH2 cells with a pCAGGS-FLPe transient vector to facilitate recombination. 
Successfully targeted colonies were selected using puromycin (1 μg/ml) and hygromycin 
(50-100 μg/mL). 
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Fgf4-/- mouse ES cells (Kang et al. 2013) were kindly supplied by Anna-Katerina Hadjantonakis. 
Lily Cho replicated the Gata6-inducible system in these cells by integrating the M2-rtTA 
tetracycline-responsive transactivator into the endogenous Rosa26 locus followed by targeting 
with the frt-neomycin/hygromycin-pA vector into the Col1A locus. Targeted cells were selected 
with puromycin (1 μg/ml) and neomycin (200 µg/mL). Double targeted Fgf4-/- cells were then 
electroporated with the pgkATG-Gata6 and pCAGGS-FLPe vectors, and successfully targeted 
colonies were selected using hygromycin (50-100 μg/mL). 
 
1.3. Doxycycline induction of transgene expression  
Transgene expression was induced 24 hours after mouse ES cells were plated, with doxycycline 
added at a final concentration of 1 mg/mL to serum and LIF (KSR+LIF) media, LIF-deficient 
media or media supplemented with FGF and Heparin, as required. Recombinant FGF4 (R&D) 
was used at 1 µg/ml, with Heparin at 1 µg/ml. Transgene expression was induced for up to 6 
days (144 hours) and samples collected at defined timepoints as required. 
 
Gata6-inducible Fgf4-/- mouse ES cells were cultured in 2i+LIF for at least 3 passages prior to 
experimental setup, and doxycycline induction was carried out in serum-free neurobasal 
medium on gelatin. For Pou5f1 knockdown experiments, shRNAs were introduced into Gata6-
inducible mouse ES cells concomitant with doxycycline induction in KSR+LIF. Five distinct 
constructs were used over three experiments. 
 
For Gata6 pulse chase experiments, transgene expression was induced with doxycycline-
containing KSR+LIF for the required pulse period. Media was then aspirated and cells washed 
twice with pluripotency media, and then cultured in fresh pluripotency media for the 48-hour 
chase. 
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1.4. GATA6 lentiviral induction 
Lentiviral packaging in HEK293T cells was carried out by Ignacio del Valle, using either 
Lipofectamine 3000 (Life Technologies) or X-fect transfection reagent (Clontech). HEK293T 
cells were kindly provided by Lucas Baltussen and Sila Ultanir. Packaging plasmids were co-
transfected with a plasmid containing human HA-tagged GATA6 and a puromycin resistance 
gene under control of an EF1a promoter (AMSbio). Lentiviral supernatants were obtained and 
concentrated by ultracentrifugation. 
 
Mouse ES or NS5 cells were plated on gelatin-coated tissue culture plates 24 hours before 
transduction so as to be 70-80% confluent at the time of transduction. Cells were transduced 
with the HA-GATA6 lentivirus for 12 hours, and then switched to media containing 1 µg/mL 
puromycin (Sigma) for selection. For ZHBTc4 Oct4 conditional knockout mouse ES cells, after 
12 hours cells were switched to media supplemented with 1 mg/ml doxycycline as well as 
1 µg/ml puromycin. 
 
1.5. Esrrb overexpression in Gata6-induced cells 
Gata6-inducible mouse ES cells were plated on gelatin-coated tissue culture plates 24 hours 
before transfection so as to be 70-80% confluent at the time of transfection. pCAGIP-Myc-Esrrb 
(Uranishi et al. 2013) or PpyCAG-FLAG-Esrrb (van den Berg et al. 2008) plasmids were 
introduced using the X-fect transfection reagent (Clontech), following the manufacturer’s 
instructions. Cells were supplemented with 1 mg/mL doxycycline concomitant with transfection, 
and samples collected and analysed 24 hours later. 
 
2. Mouse embryo harvest and culture 
6 weeks-old female Parkes or B5/EGFP mice were naturally mated. After detection of a vaginal 
plug (E0.5), females were sacrificed and oviducts dissected and removed to a petri dish 
containing drops of M2 media (made in-house, according to Jackson Laboratories protocol) at 
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room temperature. Piercing the ampulla released the clutch of zygotes into a drop of 
hyaluronidase solution, where they remained for a few minutes in order to remove the cumulus 
cells. Zygotes were then collected and washed through several drops of M2 media before being 
transferred to a micro drop culture plate containing equilibrated KSOM media (made in-house, 
according to Jackson Laboratories protocol), overlaid with mineral oil (Sigma). Zygotes were 
washed through several drops of KSOM media, then transferred to fresh drops of equilibrated 
KSOM media and cultured at 37°C, 5% CO2, to specific stages of development.  
 
In instances where mouse embryos were used to test growth factor toxicity prior to human 
embryo culture, embryos were cultured in individual drops of Global media (Life Global) 
supplemented with growth factors or inhibitors as required. For further analysis, embryos were 
routinely fixed in 4% paraformaldehyde (Sigma) for 1 hour on ice. 
 
2.1. Chimera generation following Gata6 pulse-chase induction 
For chimera generation, cells were injected into the blastocoel cavity of E2.5 – E3.5 B5/EGFP 
blastocysts (Hadjantonakis et al. 1998). To investigate contribution to the primitive endoderm, 
single cells were injected and embryos cultured in KSOM till E4.5, then fixed for further analysis. 
To investigate contribution to ExEn-derived tissues, 3 to 5 cells were injected per embryo and 
embryos transferred to the uterus of E2.5 vas plugged females. Kathy Niakan then performed 
dissections for embryo retrieval between E5.5 and E6.5. Cell injections and blastocyst transfer to 
recipient females were carried out by the Genetic Manipulation Services (GEMS) core facility. 
 
3. Human embryo and ES cell culture conditions 
3.1. Human embryo thaw and culture 
Cryopreserved human embryos surplus to family building were donated to the research project 
by informed consent under the UK Human Fertilisation and Authority Licence number R0162. 
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Embryos were thawed according to the requirements of the embryo developmental stage, and of 
the particular method and devices used for initial cryopreservation. Vitrified embryos were 
thawed using Vit Kit®-Thaw (Irvine Scientific) reagents. Slow frozen embryos were thawed 
using Quinn's Advantage Thaw Kit (Sage) or BlastThawTM (Origio) reagents. Embryos frozen in 
straws were thawed by quickly transferring the contents of the straw from liquid nitrogen onto a 
petri dish for embryo retrieval, or directly into thaw solution. Embryos frozen in Cryopette® 
devices were first thawed for 3 seconds in a 37oC water bath before transfer. Embryos frozen in 
glass ampoules were thawed completely in a 37°C water bath before transfer, after the top of the 
vial was removed under liquid nitrogen. 
 
Embryos were routinely cultured in micro drops of Global Media (Life Global) supplemented 
with 5 mg/mL Life Global Protein Supplement and overlaid with mineral oil (LiteOil, Life 
Global). Drops were pre-equilibrated overnight in an incubator at 37oC, 5% CO2. For growth 
factor treatment, these conditions were supplemented with the following recombinant human 
proteins: FGF2 (R&D) at 100 ng/ml, or at 1 µg/ml with 1 µg/ml heparin; IGF1 (R&D) at 1.7 nM 
or 17 nM; Activin A (R&D) at 10 ng or 50 ng, as indicated in the text. For TGFβ/Nodal 
signalling inhibition, media was supplemented with 40 µM SB-431542 (Sigma).  
 
3.2. Routine maintenance of human ES cells 
H1 and H9 human ES cells (WiCell) were generally cultured on Matrigel-coated (BD 
Biosciences) tissue culture plates in mTeSR1 media (Stemcell Technologies). Human ES cells 
were passaged as clumps using ReLeSR (Stemcell Technologies). Briefly, ReLeSR was added to 
wells for 30 seconds and removed, then plates were incubated for 5 minutes at 37°C, quenched 
with mTeSR and lightly tapped to dislodge clumps of the desired size. H1 and H9 cells were also 
adapted to plates coated with 1 µg/cm2 laminin-511 (Biolamina, Takara) in mTeSR1. Cells on 
laminin-511 were also passaged with ReLeSR, but with a 7 minute incubation at 37°C.  
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Human cells were frozen down in a minimal volume of 10% DMSO in serum as standard. When 
thawed, cells were resuspended in the relevant culture media and washed thrice to remove traces 
of freezing medium (cells were pelleted by centrifugation, supernatant was aspirated and 
replaced with fresh media) before plating for culture.  
 
3.3. Doxycycline inducible GATA6 lentiviral induction of human ES cells 
Doxycycline-inducible GATA6-expressing human ES cells were generated by Ignacio del Valle 
using the Lenti-X Tet-On 3G inducible expression system (Clontech), according to the 
manufacturers protocol. Briefly, the HA-tagged human GATA6 coding sequence was sub-cloned 
into the pLVX-TRE3G vector provided. HEK 293T cells were then transfected with the resulting 
pLVX-TRE3G-hGATA6-HA, or with a pLVX-Tet3G vector, using the X-fect reagent (Clontech). 
Lentiviral supernatants were concentrated using the Lenti-X Concentrator (Clontech). H9 
human ES cells were then sequentially transduced with the pLVX-Tet3G and the pLVX-TRE3G-
hGATA6-HA lentiviruses, with selection with G418 (250 μg/ml) for at least four passages prior 
to the second transduction. Human GATA6 expression was induced with doxycycline at a 
concentration of 1 mg/ml. 
 
4. Molecular analysis 
4.1. Western Blotting 
Whole cell protein was extracted with CelLytic M reagent (Sigma) supplemented with proteinase 
and phosphatase inhibitors (Roche). 30 µg of protein per sample was resolved on 12% SDS-
PAGE gels and transferred to a PVDF membrane using a BioRad Trans-Blot transfer system 
(BioRad). Membranes were blocked in TBS and 0.1% Tween (Sigma) with 5% skimmed milk, or 
5% BSA (Sigma) for detection of phosphorylated proteins, and incubated with primary antibody 
at 4°C overnight. Following washes in TBS 0.1% Tween, membranes were incubated with 
secondary antibody in 5% milk or 5% BSA for one hour at room temperature. Proteins were 
visualized using the Pierce ECL Western Blotting Substrate (Thermo) with film exposure. 
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4.2. Immunofluorescence and imaging 
Embryos and ES cells were fixed in 4% paraformaldehyde at 4°C for 1 hour or overnight 
respectively, then permeabilized with PBS 0.5% Tween for 20 minutes and blocked with 10% FBS 
(Life Technologies) in PBS 0.1% Tween for 1 hour. Primary antibodies were diluted at 1:500 in 
blocking solution and samples incubated at 4°C rotating overnight. Secondary antibodies were 
diluted at 1:300 in blocking solution and samples incubated for 1 hour at room temperature, 
then washed and covered with PBS 0.1% Tween containing DAPI Vectashield mounting 
medium (Vector Labs). 
 
Embryos were imaged on a Leica SP5 inverted confocal microscope (Leica Microsystems) at a z-
section thickness of 3μm or 2 μm for human or mouse embryos respectively. ES cells were 
imaged using an Olympus 1X71 microscope with Cell^F software (Olympus Corporation, 
Tokyo, Japan), Zeiss Axiovert 200M microscope with AxioVision Rel 4.7 software (Carl Zeiss 
Ltd., Jena, Germany).  
 
MINS 1.3 software was used to analyse immunofluorescence in embryos (http://katlab-tools.org/) (Lou et al. 2014). Confocal stacks in .tif format were loaded into the MINS pipeline 
for automated nuclear detection and segmentation to determine the number of cells in each 
embryo.  The MINS segmentation output was manually checked for appropriate segmentation 
and mitotic nuclei were removed from the analysis. Data were subsequently plotted using 
GraphPad Prism version 7 (GraphPad Software, La Jolla, CA). 
 
4.3. Quantitative RT-PCR (qRT-PCR) 
RNA was isolated using TRI Reagent (Sigma) and DNaseI treated (Ambion). cDNA was 
synthesized using a Maxima First Strand cDNA Synthesis Kit (Fermentas). qRT-PCR was 
performed using Quantace Sensimix on an Applied Biosystems 7500 machine (Life Technologies 
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Corporation, California, USA). Primer pairs were previously published (Brown et al., 2010a; 
Fujikura et al., 2002; Molkentin et al., 1997; Niwa et al., 2005) or designed using Primer3 
software. Primers are listed in the Reagents section. 
 
4.4. Flow cytometry 
Cells were dissociated using 0.05% Trypsin-EDTA, then washed twice and resuspended in FACS 
fixing buffer (1% paraformaldehyde, PBS 0.01% Tween) for 20 minutes on ice. Cells were washed 
twice with permeabilisation buffer (5% FBS, PBS 0.05% Tween) then incubated with Nanog 
primary antibody (REC-RCAB0001P, 2B Scientific) and FITC anti-rabbit secondary antibody 
(A21206, Alexa Fluor) at a 1:250 dilution in permeabilisation buffer for 20 minutes on ice. Cells 
were washed twice then resuspended in permeabilisation buffer for analysis. Cells were analysed 
on a BD Fortessa X20 flow cytometer (BD Biosciences). FlowJo software (BD Biosciences) was 
used to generate histogram overlays and dot plots. 
 
4.5. Microarray analysis 
Total RNA was isolated as above and DNaseI treated (Ambion). RNA quality was assessed on a 
Eukaryote Total RNA Nano Series II (Agilent Technologies, Santa Clara, CA, USA) then 
processed on an Agilent 2100 Bioanalyzer using the RNA electrophoresis program. All RNA 
samples were amplified using the Total Prep 96 RNA amplification kit (Ambion). Samples were 
hybridized to Illumina MouseWG-6_V2 expression BeadChip arrays (Illumina, Inc. California, 
USA) Biological triplicates were collected for each sample. Details of computational analysis can 
be found in Wamaitha et al., 2015, Supplemental Experimental Procedures. Data is available via 
the Gene Expression Omnibus (GSE69321). 
 
4.6. Chromatin immunoprecipitation sequencing (ChIP-seq) 
Gata6-inducible mouse ES cells were seeded at 1 x 104 cells/cm2 and treated with 1mg/mL 
doxycycline for 36 hours prior to harvesting. Immunoprecipitation was performed on 1-2 x107 
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cells as described (Vokes et al. 2007) for three biological replicates versus input samples. 
Sonication was performed using a Misonix 4000 (28 cycles: 15 seconds on and 45 seconds off at 
an intensity of 70%) with a Microtip Probe (Misonix, Farmingdale, NY). Antibodies used are 
listed in the Reagents section.  Libraries were prepared using the TruSeq ChIP Sample 
Preparation Kit and the resulting samples were sequenced using Illumina Genome Analyzer II 
(Illumina, San Diego, CA). Details of computational analysis can be found in (Wamaitha et al. 
2015), Supplemental Experimental Procedures. Data is available via the Gene Expression 
Omnibus (GSE69322). 
 
4.7. RNA sequencing 
RNA was isolated from untransduced and Gata6-transduced human ES cells using TRI Reagent 
(Sigma) and DNaseI treated (Ambion). Libraries were prepared using the TruSeq RNA Library 
Preparation Kit v2 (Illumina). Quality of total RNA and subsequent cDNA library preparations 
was assessed on a 2100 Bioanalyzer (Agilent). Libraries were submitted for 50-bp paired-end 
sequencing on an Illumina HiSeq 2000 (Illumina). Details of computational analysis can be 
found in (Wamaitha et al. 2015), Supplemental Experimental Procedures. Data is available via 
the Gene Expression Omnibus (GSE69322). 
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5. Reagents 
5.1 KSR media composition (500 ml) 
Component  Supplier  
Catalogue 
Number  
Stock 
Concentration  
Final 
concentration  Volume  
Advanced 
DMEM/F12 
Invitrogen 12634-010 - 78% 390 ml 
Knockout serum 
replacer (KOSR) 
Invitrogen 10828028 - 20% 100 ml 
L-glutamine Invitrogen 25030-024 200 mM 2 mM (1%) 5 mL 
β mercaptoethanol Sigma M6250 14.3 M 0.1 mM 3.5 μl 
Penicillin/ 
Streptomycin 
 
Sigma 15140-122 100% 1% 5 ml 
 
5.2 MEF media composition (500 ml) 
Component  Supplier  
Catalogue 
Number  
Stock 
Concentration  
Final 
concentration  Volume  
Advanced 
DMEM/F12 
Invitrogen 12634-010 - 88% 440 ml 
Foetal Bovine Serum 
(FBS) 
Bioserum S1818 - 10% 50 ml 
L-glutamine Invitrogen 25030-024 200 mM 2 mM (1%) 5 mL 
β mercaptoethanol Sigma M6250 14.3 M 0.1 mM 3.5 μl 
Penicillin/ 
Streptomycin 
 
Sigma 15140-122 100% 1% 5 ml 
 
5.3. XEN media composition (500 ml) 
Component  Supplier  
Catalogue 
Number  
Stock 
Concentration  
Final 
concentration  Volume  
RPMI 1640 Invitrogen 61870-010 - 83% 415 ml 
Foetal Bovine Serum 
(FBS) 
Bioserum S1818 - 15% 75 ml 
L-glutamine Invitrogen 25030-024 200 mM 2 mM (1%) 5 mL 
β mercaptoethanol Sigma M6250 14.3 M 0.1 mM 3.5 μl 
Penicillin/ 
Streptomycin 
 
Sigma 15140-122 100% 1% 5 ml 
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5.4. Antibodies 
Primary Antibody Supplier Catalogue Number Application Species 
Dilution and 
Reactivity* 
Actin Millipore MAB1501 WB Mouse 1:10000 
Esrrb R&D PP-H6705-00 IHC Mouse 1:500 
FLAG Sigma F1804 IHC/WB/ChIP Mouse 
1:500/1:1000/
9mg per mL 
Gata4 
Santa Cruz 
Biotech 
SC-9053 IHC/WB Rabbit 1:500/1:1000 
Gata6 R&D AF1700 IHC/WB Goat 
1:500/1:1000 
Mouse 
Gata6 
Santa Cruz 
Biotech 
SC-9055 IHC Rabbit 
1:500 
Human 
HA Roche 11867423001 IHC Rat 1:500 
Total p44/42 MAPK 
(Erk1/2) 
Cell 
Signalling 
4695 WB Rabbit 1:2000 
Phospho  
p44/42 MAPK 
Cell 
Signalling 
9101 WB Rabbit 1:1000 
Nanog 
2B 
Scientific 
REC-
RCAB0001P 
IHC/WB Rabbit 
1:1000 
Mouse 
Nanog R&D AF1977 IHC Goat 
1:500 
Human 
Oct4 
Santa Cruz 
Biotech 
SC-5279 IHC/WB Mouse 1:500/1:1000 
Sox2 R&D AF2018 WB Goat 1:1000 
Sox7 R&D MAB2766 IHC Goat 1:500 
Sox17 R&D AF1924 IHC/WB Goat 1:500/1:1000 
*If not specifically indicated, antibody is reactive in both mouse and human. 
Secondary Antibody Supplier Catalogue No. Application Species Dilution  
Alexa Fluor 
anti-mouse IgG 
Invitrogen 
A21202 (488) 
A21203 (594) 
A31571 (647) 
IHC Donkey 1:300 
Alexa Fluor  
anti-rabbit IgG 
Invitrogen 
A21206 (488) 
A21207 (594) 
A31573 (647) 
IHC Donkey 1:300 
Alexa Fluor 
anti-goat IgG 
Invitrogen 
A11055 (488) 
A11058 (594) 
A21447 (647) 
IHC Donkey 1:300 
Goat IgG (H+L),  
HRP conjugated 
Santa Cruz SC-2020 WB Goat 1:20000 
Mouse IgG (H+L), HRP 
conjugated 
Cell 
Signalling 
7076 WB Mouse 1:20000 
Rabbit IgG (H+L), HRP 
conjugated 
Cell 
Signalling 
7074 WB Rabbit 1:20000 
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5.5. Mouse qRT-PCR primer pairs 
Name Forward Primer Reverse Primer 
Col4a1 GGTCCTGTCTGGAAGAGTTT AAATACAATGGGAGGGAGAA 
Dab2 GGCAACAGGCTGAACCATTAGT TTGGTGTCGATTTCAGAGTTTAGAT 
Esrrb 3’UTR CCTCCACTTTCCCCTTTCTT AGGTTTCTAGACTGGCCATG 
FLAG CAAAGACCATGACGGTGATTA TCGTCATCCTTGTAGTCGATG 
Foxa3 3’UTR GGCTGTGTGCCTCAGGTCGG CTCCGGTGCTGCCACCAGTG 
Gapdh AATGGAATACGGCTACAGC GTGCAGCGAACTTTATTG 
Gata4 3’UTR TTCCTGCTCGGACTTGGGAC TGGACAGGCAGGTGGAGAATAAG 
Gata6 3’UTR ACAGCCCACTTCTGTGTTCCC GTGGGTTGGTCACGTGGTACAG 
V5 CGGTTCGAAGGTAAGCCTAT ATGGTGATGGTGATGATGA 
Hnf4a 3’UTR CAACGATCACCAAGCAAGAA CTGGGGTCTTCTCAAGCAAA 
Lama1 AGGTCTGCGTTGAGTGTTCTG CAGTACTATGCCGTCAGCGAT 
Nanog AGCAGATGCAAGAACTCTCCTC AAGTTGGGTTGGTCCAAGTCT 
Pou5f1 AGAAGTCCCAGGACATCAAA TGCTTTGCATATCTCCTGAA 
Prdm14 3’UTR ATTTGGTTTTGGTGGTGGTG CCTGGCATTTTCATTGCTCA 
Sox2 TAGAGCTAGACTCCGGGCGATGA TTGCCTTAAACAAGACCACGAAA 
Sox7 3’UTR AACACTCCCGGCCACCCTGA AAGGAGCGCTGGATCCTGGCT 
Sox17 3’UTR AAGAAACCCTAAACACAAACAGCG TTTGTGGGAAGTGGGATCAAGAC 
Sparc1 AGGGCCTGGATCTTCTTTCTC CAAATTCTCCCATTTCCACCT 
 
5.6. Human qRT-PCR primer pairs 
Name Forward Primer Reverse Primer 
AFP ACCATGAAGTGGGTGGAATC TGGTAGCCAGGTCAGCTAAA 
GATA6 TCCACTCGTGTCTGCTTTTG TCCTAGTCCTGGCTTCTGGA 
HA-GATA6 AACACAACCTACAGCCTCAG GACGTCATAAGGGTAGGCC 
NANOG GCAACCTGAAGACGTGTGAA CTCGCTGATTAGGCTCCAAC  
POU5F1 TATGGGAGCCCTCACTTCAC  CAAAAACCCTGGCACAAACT  
SOX2 TTGTTCGATCCCAACTTTCC ACATGGATTCTCGGCAGACT  
SOX7 ACGCCGAGCTCAGCAAGAT TCCACGTACGGCCTCTTCTG 
SOX17 CGCACGGAATTTGAACAGTA GGATCAGGGACCTGTCACAC 
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Results and Discussion 
 
1. FGF signalling dynamics and lineage specification in mouse ES cells 
The precise mechanism by which ICM cells in the early embryo diverge to favour either a 
pluripotency or an ExEn gene regulatory network remains unclear. However, activation of FGF 
signalling has been shown to be required for PrE specification, and derivation of mouse XEN 
cells requires FGF, though endogenous levels are sufficient (Feldman et al. 1995; Arman et al. 
1998; Kunath et al. 2005; Chazaud et al. 2006; Yamanaka et al. 2010; Cho et al. 2012; Grabarek et 
al. 2012; Kang et al. 2013; Niakan and Eggan 2013). FGF signalling has also been linked to mouse 
ES cell differentiation (Kunath et al. 2007; Stavridis et al. 2007; Ying et al. 2008; Cho et al. 2012). 
 
A reciprocal FGF receptor-ligand relationship is thought to exist between the PrE and Epi 
lineages within the mouse ICM (Guo et al. 2010), and this correlates with the effects of FGF 
signalling modulation in the embryo. FGF stimulation converts all ICM cells to PrE (Chazaud et 
al. 2006; Yamanaka et al. 2010), likely by destabilising the balance of receptor-enriched PrE 
versus receptor-deficient Epi. Conversely, mutations in FGF signalling pathway components 
limit all cells within the ICM to an Epi fate (Feldman et al. 1995; Arman et al. 1998; Cheng et al. 
1998). Given that inhibiting Mek phenocopies mutations of upstream FGF signalling 
components (Nichols et al. 2009; Yamanaka et al. 2010), its downstream target, Erk, is likely to 
be involved in these lineage decisions. 
 
Previous studies in mouse ES cells indicate that FGF signalling functions via the Raf-Mek-Erk 
MAPK pathway to disrupt pluripotency (Burdon et al. 1999; Ying et al. 2008). Two Erk 
homologues, Erk1 and Erk2 are present in mammalian cells, but only Erk2 has an embryonic 
lethal phenotype (Pages et al. 1999; Hatano et al. 2003), and is thus likely to be the more 
developmentally relevant kinase. However, it is unclear precisely how Erk phosphorylation 
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induces these cell fate choices, and whether this is linked to the nuclear localisation dynamics 
observed in other contexts (Robinson et al. 1998; Brunet et al. 1999; Costa et al. 2006). 
 
In this chapter, I investigate Erk localisation dynamics in mouse ES cells and the E3.5 
preimplantation embryo, as well as exploring the relationship between FGF/Erk signalling and 
the PrE-associated factor Gata6 during ES to XEN cell reprogramming. 
 
1.1. FGF signalling and Erk localisation in mouse ES cells 
In alternative contexts, Mek phosphorylates Erk and triggers Erk nuclear translocation, resulting 
in cell proliferation and differentiation mediated by Erk targets (Robinson et al. 1998; Brunet et 
al. 1999; Costa et al. 2006). However, it is unclear if a similar translocation occurs following FGF 
stimulation and MAPK pathway activation in mouse ES cells. Indeed, the effect of FGF signalling 
in mouse ES cells beyond Mek and Erk, and how this impacts the pluripotency regulatory 
network, is only just beginning to be elucidated. Erk may function mainly to target and regulate 
core pluripotency regulatory elements via direct phosphorylation, such as Klf4 (Kim et al. 2012), 
or also indirectly regulate key transcriptional or protein regulatory mechanisms via additional 
factors. In addition, visualising Erk localisation and phosphorylation dynamics in the early 
embryo may also determine whether localisation correlates with, or perhaps even predicts, PrE 
cell fate specification. Consequently, a principle aim of this project was to characterise FGF/Erk 
signalling dynamics and their relationship to lineage segregation in vivo and ES cell 
differentiation in vitro. 
 
1.1.1 Erk2 phosphorylation correlates with nuclear localisation in vitro 
To investigate Erk2 localisation patterns in mouse ES cells, Erk2 fluorescent reporter lines were 
generated (in collaboration with Russell Ernst). Wild type mouse ES cells were transfected with a 
targeting construct that would fuse a Venus tag in frame with the final C-terminal exon of one 
Erk allele via homologous recombination (Figure 1.1A). Successfully targeted ES cell colonies  
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were selected using hygromycin and correct insertion confirmed by PCR genotyping (Figure 
1.1B). Western blot analysis confirmed expression of the Erk2-Venus fusion protein, detected by 
both anti-GFP and anti-total Erk antibodies (Figure 1.1C). 
 
Previous studies have shown by western blot analysis that Erk phosphorylation in mouse ES cells 
increases from as early as 10 minutes following FGF stimulation (Hamilton et al. 2013), though it 
is unclear whether this correlates with nuclear localisation in individual cells. Consequently, the 
Erk2-Venus fusion presents a promising means of linking localisation dynamics to protein 
activity. In, preliminary live imaging experiments, Erk2-Venus mouse ES cells were treated with 
1 µg/ml FGF2 and examined at defined timepoints to monitor localisation dynamics (Figure 
1.2A). Although Fgf2 is not expressed in the early mouse embryo (Guo et al. 2010), both it and 
Fgf4 function via the Fgfr2 receptor, and these ligands have been used interchangeably to 
stimulate FGF signalling (Kunath et al. 2005; Cho et al. 2012). 
 
Erk2-Venus was initially localised in the cytoplasm of the majority of cells maintained in serum 
and LIF, but nuclear translocation was observed following FGF stimulation over a 12-minute 
period (Figure 1.2A). Immunofluorescence analysis for phosphorylated Erk was next performed 
to compare untreated cells and cells stimulated with FGF for a longer period. Some 
phosphorylated Erk was detected in the cytoplasm of untreated cells (Figure 1.2B), likely due to 
the presence of serum and LIF, which are both known to stimulate Erk phosphorylation (Smith 
et al. 2004; Kunath et al. 2007). However, nuclear-localised phosphorylated Erk, overlapping 
with Erk2-Venus, was observed in a number of cells after 30 minutes of FGF treatment (Figure 
1.2B). Consequently, FGF stimulation appears to specifically correlate with Erk nuclear 
localisation, to contrast to serum and LIF. 
 
As FGF stimulation seemingly correlated with Erk2 nuclear localisation in vitro, experiments 
were set up to determine the Erk2 localisation patterns in the E3.5 mouse blastocyst. Given that  
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stimulating or inhibiting FGF signalling in vivo results in conversion of ICM cells to either all 
PrE or Epi cells respectively (Chazaud et al. 2006; Nichols et al. 2009; Yamanaka et al. 2010), 
Erk2 nuclear localisation may correlate with cell fate in the embryo. E3.5 blastocysts were stained 
for phosphorylated or total Erk, and Sox17 and Oct4 were used to identify PrE and Epi cells 
respectively within the ICM (Figure 1.2C). Oct4 is expressed in all ICM cells at this 
developmental stage (Dietrich and Hiiragi 2007), so Oct4-positive Sox17-negative cells within 
the ICM were designated as Epi cells.  Although Nanog is a more specific epiblast marker, 
antibody species restrictions prevented it from being used in tandem with phosphorylated Erk.  
 
Curiously, phosphorylated Erk was not specifically nuclear localised in either Epi or PrE cells 
(Figure 1.2C), and all cells within the embryo exhibited dispersed phosphorylated Erk 
distribution. The same distribution pattern was observed for total Erk protein (Figure 1.2C). This 
may indicate that although a latent level of phosphorylated Erk is present in all cells in the 
embryo, alternative factors influence an Epi or PrE cell fate choice, which is then reinforced by 
Erk signalling. Alternatively, differential Erk localisation could be present earlier than the E3.5 
stage that was analysed, or could be dynamically oscillating such that the finer details would not 
be captured by static timepoints. 
 
To better investigate the dynamics of Erk2 localisation during early embryonic development, it 
was decided to establish an Erk2-Venus reporter mouse line by introducing Erk2-Venus ES cells 
into recipient embryos to generate chimeras and then subsequent breeding to derive a 
homozygous line. Live imaging of Erk-Venus reporter embryos would elucidate Erk localisation 
patterns during early embryonic development, and enable investigations into how modulating 
FGF signalling alters any observed translocation dynamics. Furthermore, Erk2Venus/Venus mice 
could also be crossed with Epi or PrE reporter lines to tally localisation with cell fate 
specification. This work is still on going. 
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1.2. FGF signalling and lineage specifiers in mouse ES cells 
Whilst the initial Erk localisation experiments were in progress, it was reported that Erk 
signalling in vitro was only specifically required for endodermal differentiation, where its 
primary function was to suppress pluripotency (Hamilton and Brickman 2014). Nanog 
downregulation following Erk signalling activation preceded any detectable increase in the 
expression of the PrE-associated factor Gata6. This is consistent with studies suggesting that Erk 
may indirectly promote upregulation of an ExEn gene network by suppressing pluripotency 
factors such as Nanog (Hamazaki et al. 2006), which has been shown to repress Gata6 (Singh et 
al. 2007). Consistent with this, previous studies demonstrated that Erk directly phosphorylated 
and inhibited the transcriptional activity of the pluripotency-associated factor Klf4 (Kim et al. 
2012), which has been shown to positively regulate Nanog expression in mouse ES cells (Zhang 
et al. 2010). 
 
Interestingly, overexpression of Gata6, or the closely related zinc finger transcription factor 
Gata4, is sufficient to reprogram mouse ES cells into XEN-like cells that contribute to PrE-
derived lineages in vivo (Fujikura et al. 2002; Shimosato et al. 2007). Gata6 has also been shown 
to directly regulate endoderm-associated genes such as Hnf4a and Dab2 (Morrisey et al. 1998; 
Morrisey et al. 2000). In addition, XEN cells can be generated by growth factor-mediated 
conversion protocols that require FGF signalling, and Gata6-/- cells are refractory to this 
conversion (Cho et al. 2012; Niakan and Eggan 2013). Reprogramming mouse ES cells to XEN 
cells involves downregulation of the existing pluripotency network (Fujikura et al. 2002; 
Shimosato et al. 2007; Cho et al. 2012), though how this occurs remains unclear, and it is possible 
that Erk and Gata6 function in tandem to drive this fate switch. To explore this further, I sought 
to next investigate the relationship between Gata6 and FGF/Erk signalling during mouse ES cell 
differentiation. 
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1.2.1: Gata6 OE can bypass a requirement for FGF signalling 
Mouse ES cell lines expressing a single copy of tetracycline/doxycycline-inducible Gata6 
transgene had previously been generated within our lab (Lily Cho, Kathy Niakan) using a site-
specific recombination-based integration strategy (Hochedlinger et al. 2005; Beard et al. 2006). 
Briefly, the Gata6 cDNA sequence was amplified from eXEN cell lines and integrated into the 
Col1a locus under the control of a tetracycline operator minimal promoter in KH2 mouse ES 
cells, which had been modified to include an M2-rtTA tetracycline-responsive transactivator 
under the control of the Rosa26 promoter. A FLAG-tag was also integrated in order to 
distinguish the transgene from the endogenous protein. Control mouse ES cells were generated 
by integrating a gene encoding a red fluorescent protein, dsRed into the Col1a locus (Wamaitha 
et al. 2015). The Gata6 transgene was also integrated (Lily Cho) into Fgf4-/- mouse ES cells (Cho 
et al. 2012; Kang et al. 2013) in a similar fashion. Following doxycycline induction, robust red 
fluorescence was observed in the control dsRed transgenic line, confirming the fidelity of the 
transgene system (Fig. 1.3A).  
 
For initial characterisation, the wild type Gata6 transgenic line was treated with doxycycline for 
6 days in the presence of LIF and serum, conditions that would otherwise maintain mouse ES 
cell self-renewal indefinitely in culture. The Fgf4-/- Gata6-transgenic cells were first grown for 
three passages in MEF-free conditions with serum-free media in the presence of an Erk and Gsk3 
inhibitor together with LIF (2i+LIF, (Ying et al. 2008)), to eliminate the possibility of signalling 
from exogenous FGFs. Gata6 expression was then induced for 6 days in serum-free media.  
 
Wild type Gata6-induced cells exhibited a rapid morphological conversion (Figure 1.3B), 
changing from conventional mouse ES cell colonies to single cells with the dispersed, refractile 
and stellate morphology characteristic of embryo-derived XEN (eXEN) and growth-factor 
converted XEN (cXEN) cells (Kunath et al. 2007; Cho et al. 2012). XEN-like cells derived  
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following transgene overexpression were referred to as induced XEN (iXEN cells) to distinguish 
them from their embryo-derived counterparts (eXEN cells).  
 
qRT-PCR analysis at defined timepoints over the 6-day timecourse confirmed that both wild 
type and Fgf4-/- Gata6-overexpressing cells downregulated pluripotency factors Nanog, Pou5f1 
and Sox2 over the 6 day timecourse (Figure 1.3C). Nanog and Sox2 transcripts were rapidly 
downregulated within 12 hours of doxycycline induction, while Pou5f1 transcript displayed 
prolonged expression until 48 hours post induction, but was downregulated after 96 hours 
(Figure 1.3C). Endogenous Gata6 was also upregulated (distinguished from the FLAG-tagged 
transgene using primers targeted to the endogenous 3’-UTR sequence), as well as key ExEn genes 
including Gata4, Sox17, Lama1, Col4a1 and Sparc (Fig 1.3C). This is consistent with 
observations in Fgf4-/- and dominant-negative Fgfr2 mutant mouse ES cells transiently 
transfected with Gata6 (Li et al. 2004; Kang et al. 2013).  
 
To investigate if exogenous FGF signalling would influence the dynamics of the induction, 
doxycycline treatment in Fgf4-/- Gata6-overexpressing cells was repeated in media supplemented 
with Fgf4 and the FGF receptor binding facilitator heparin (Yayon et al. 1991). Similar gene 
upregulation and downregulation trends were observed for Fgf4-/-Gata6-induced cells in FGF-
supplemented compared to standard media (Fig 1.3C), suggesting FGF signalling has no additive 
effect. Western blot analysis of selected proteins in Fgf4-/- Gata6-induced cells after 6 days of 
induction confirmed loss of pluripotency factors and elevated expression of ExEn genes (Fig 
1.3D). Phosphorylated Erk was not detected (Figure 1.3D), suggesting that active Erk signalling 
is not required for this conversion, and that downregulation of the pluripotency network is 
occurring via alternative means. 
 
Following the 6-day doxycycline induction, Fgf4-/- Gata6-induced cells were passaged and 
switched to XEN cell maintenance media (Kunath et al. 2007) without supplementation with 
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FGF and heparin, in an attempt to establish a stable iXEN cell line. Fgf4-/- iXEN cell lines were 
maintained for more than two months in the absence of doxycycline without loss of ExEn gene 
expression or XEN-like morphology (Fig. 1.3E, Fig. 1.3F), suggesting there is no requirement for 
a feedback loop upregulating Fgf4 to reinforce Gata6-mediated reprogramming. Altogether, this 
suggests that Gata6 can drive a XEN cell fate switch in vitro independent of endogenous FGF. 
 
1.2.2. Gata6 OE can also bypass a requirement for Oct4 
In addition to its role in promoting pluripotency, Oct4 has also been shown to be required for 
Fgf4-mediated primitive endoderm specification within the mouse embryo (Frum et al. 2013; Le 
Bin et al. 2014). Oct4 and Nanog regulate expression of Fgf4 (Nichols et al. 1998; Frankenberg et 
al. 2011), and although Gata6 expression is initiated in Oct4 or Nanog mutant embryos, the 
subsequent absence of Sox17 and Gata4 suggests that primitive endoderm formation is 
compromised (Frankenberg et al. 2011; Frum et al. 2013; Le Bin et al. 2014; Schrode et al. 2014). 
Although addition of exogenous FGF can restore Sox17 expression in these embryos, later PrE 
derivatives remain compromised. Previous studies in mouse ES cells showed that Oct4 
overexpression upregulated Gata4 expression (Niwa et al. 2000; Fujikura et al. 2002), although as 
the mesodermal marker Brachury (T) was also upregulated (Niwa et al. 2000), this suggests that 
Oct4 may not necessarily promote solely an endoderm program. 
 
To determine if Oct4 is required to upregulate the wider ExEn network following Gata6 
initiation in vitro, shRNAs directed against Pou5f1 were transduced into the wild type Gata6 
transgenic line coincident with doxycycline treatment (Ignacio del Valle). qRT-PCR analysis 
confirmed significant loss of Pou5f1 expression compared to scrambled controls (Fig 1.4A), and 
despite loss of Oct4, Gata6-induced cells still upregulated endogenous Gata6, Sox17, Gata4, 
Lama1, Col4a1, and Sparc and down-regulated pluripotency factors Sox2 and Esrrb (Fig 1.4A).  
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Western blot analysis verified the expression of Sox17 and endogenous Gata6 protein in the 
absence of Oct4 in Pou5f1 shRNA transduced cells, similar to untransduced Gata6-induced cells 
(Fig 1.4B), suggesting Oct4 is dispensable for Gata6-mediated reprogramming.  
 
To further confirm this, an Oct4 conditional knockout mouse ES cell line (ZHBTc4) was 
identified where doxycycline treatment abrogated Oct4 expression, inducing differentiation to 
trophectoderm stem (TS) cells (Niwa et al. 2000). To induce Gata6 in ZHBTc4 cells, a lentiviral 
construct expressing the human GATA6 gene downstream of an EF1a promoter was used, which 
was shown to successfully reprogram wild type mouse ES cells to iXEN cells (Fig 1.4C, 1.4D), 
analogous to the doxycycline-inducible system. The GATA6 construct was transduced 
coincident with doxycycline treatment and western blot analysis confirmed loss of Oct4 protein 
within 12 hours of doxycycline addition (Fig 1.4E). Following doxycycline exposure, flattened 
cells with the cobblestone-like morphology characteristic of TS cells emerged in the 
untransduced ZHBTc4 cells (Fig 1.4F) as previously observed (Niwa et al. 2000). In contrast, 
XEN-like cells were observed in the GATA6-transduced ZHBTc4 cultures (Fig 1.4F), consistent 
with the Pou5f1 knockdown Gata6-induced cells. Altogether, this suggests that Gata6 induction 
can also bypass a requirement for Oct4 in reprogramming mouse ES cell to iXEN cells in vitro, 
and consequently effectively drives this fate switch independently of the mechanisms required 
for PrE specification in the embryo. 
 
1.2.3. Gata6 (and Gata4) are uniquely capable lineage re-programmers, and exogenous 
FGF cannot rescue failure of other TFs 
To determine whether factors other than Gata6 could also generate iXEN cells, four additional 
ExEn-associated transcription factors - Sox7, Sox17, Hnf4a and Foxa3 - were selected based on 
their expression in the PrE or its derivatives, and whether previous studies demonstrated a 
functional requirement for establishing or maintaining the PrE (Chen et al. ; Soudais et al. 1995; 
Molkentin et al. 1997; Kaestner et al. 1998; Capo-Chichi et al. 2005; Artus et al. 2011; Schrode et 
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al. 2014). Gata4 was also included for further characterisation, as it had previously been shown 
to generate iXEN cells (Fujikura et al. 2002; Shimosato et al. 2007). Transgenic lines were 
generated (Lily Cho, Kathy Niakan) using the same site-specific recombination-based strategy 
used for the Gata6 transgenic lines, and treated with doxycycline for 6 days in the presence of 
LIF and serum.  
 
Only Gata4 induction resulted in the emergence of cells with XEN-like morphology, similar to 
those observed following Gata6 induction (Fig. 1.5A; Fig. 1.3D), as had been previously observed 
(Fujikura et al. 2002; Shimosato et al. 2007). Expression of Sox7, Sox17, Hnf4a or Foxa3 did not 
induce a morphological switch during the time period assayed (Fig. 1.5A), and qRT-PCR 
analysis revealed inconsistent upregulation of ExEn genes, with a failure to upregulate the 
expression of key factors such as Col4a1, Lama1 or Hnf4a to eXEN cell levels (Fig. 1.5B). In 
contrast, the GATA factors consistently upregulated these genes, including expression of 
endogenous Gata6 and Gata4 (Fig. 1.5B). 
 
Transgene expression was next induced in the presence of exogenous Fgf4 and heparin to test if 
this could perhaps enhance the likelihood of iXEN conversion, compensating for the inability of 
other factors to downregulate pluripotency genes. However, again only Gata4 induction 
generated iXEN cells within the 6 day time period (Fig. 1.6A). Although the Sox7-, Sox17-, 
Hnf4a- or Foxa3-induced cells lost their mouse ES cell morphology, they seemed to randomly 
differentiate, and resembled dsRed-induced control cells (Fig 1.6A). Additionally, there appeared 
to be little difference in overall gene expression between FGF-supplemented and LIF-deficient 
conditions (Fig. 1.6B), where removal of LIF would also destabilize the pluripotency network 
(Smith et al. 1988; Williams et al. 1988). Only Gata4-induced cells generated iXEN cells in LIF-
deficient media (Fig 1.6A). Altogether, this indicates that exogenous FGF signalling cannot 
compensate for the failure of certain endoderm transcription factors to reprogram mouse ES 
cells to iXEN cells. 
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Previous studies observed that although Sox17 induction can upregulate ExEn gene expression in 
mouse ES cells, Sox17-overexpressing cells retained mouse ES cell-like morphology and 
pluripotency factor expression after 48 hours of induction (Niakan et al. 2010; McDonald et al. 
2014). Similarly, levels of Pou5f1, Nanog and Sox2 in Sox17-, Sox7- or Foxa3-induced cells were 
comparable to the expression in dsRed control cells after 6 days of induction (Fig. 1.5B). To 
confirm this at the protein level, the expression of select pluripotency and ExEn factors was 
analysed in Gata6-, Sox7- and Sox17-induced cells. Immunofluorescence analysis confirmed that 
Gata6-induced cells expressed Gata4, Gata6, Sox17 and Laminin proteins, and no longer 
expressed Oct4 (Fig. 1.7A). In contrast, Sox7-induced cells persistently expressed Oct4 protein, 
with only a few cells at the periphery of mouse ES-like colonies expressing Gata4, Gata6, Sox17 
and Laminin (Fig. 1.7A). This latter expression pattern was reminiscent of the sporadic 
differentiation to XEN-like cells previously observed in wild type mouse ES cell cultures (Niakan 
et al. 2010). Consistent with this, a recent study also demonstrated that Sox7-induction is 
insufficient to generate XEN-like cells (Kinoshita et al. 2015). 
 
Western blot analysis revealed that despite robust induction of exogenous Sox17 over the 6-day 
treatment period, Sox17-induced cells retained expression of Nanog and Oct4 (Fig. 1.7B), and 
showed delayed upregulation of Gata4 compared to Gata6-induced cells (Fig. 1.7B, 1.7C). This is 
consistent with recent observations that Sox17-expressing cells only acquired XEN-like 
morphology and downregulated pluripotency factor expression after 12 and 18 days of 
induction, respectively (McDonald et al. 2014). Gata6-induced cells however, downregulated 
Nanog, Sox2 and Oct4 protein within 12, 36 and 96 hours after induction, respectively (Fig. 
1.7C). This strongly suggests that the ability of Gata6 and Gata4 to successfully drive iXEN 
reprogramming is linked to their capacity to both establish a wider ExEn gene network and 
downregulate the existing pluripotency program within a shorter time frame.  
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1.3. Characterising Gata6-mediated lineage reprogramming 
Despite upregulation of Gata4 and Sox17 transcripts within 12 hours of Gata6 induction (Fig. 
1.3C), their proteins were not detected by western blot until 24 hours following doxycycline 
treatment (Fig. 1.7C). Given that Nanog and Sox2 proteins are downregulated in the absence of 
detectable Gata4 or Sox17 protein (Fig. 1.7C), this suggests that Gata6 directly mediates initial 
downregulation of the pluripotency program. Direct regulation could also explain why Gata6 
can drive reprogramming independent of FGF/Erk-mediated disruption of the pluripotency 
network. Consequently, and as Gata6 is thought to lie upstream of Gata4 in the PrE 
transcriptional hierarchy (Morrisey et al. 1998; Koutsourakis et al. 1999; Chazaud et al. 2006; 
Plusa et al. 2008; Artus et al. 2011; Schrode et al. 2014), subsequent experiments used Gata6 
transgenic mouse ES cells to characterise how this transcription factor drives an ES to XEN fate 
switch. 
 
1.3.1. A short Gata6 induction is sufficient to perturb mouse ES cell pluripotency 
To unravel the mechanisms of Gata6-mediated reprogramming, initial experiments sought to 
determine the minimum temporal requirement for Gata6 induction to affect mouse ES cell gene 
expression. Gata6-transgenic cells were stimulated with doxycycline for defined pulses of 
between 2 and 12 hours, and then fixed for immunohistochemistry analysis immediately 
following doxycycline withdrawal (Fig. 1.8A). Exogenous FLAG-tagged Gata6 protein expression 
was detectable by immunofluorescence and western blot analysis 2 to 4 hours following 
doxycycline addition (Fig. 1.8B, 1.8C).  
 
Although induced cells retained mouse ES cell morphology at these early stages, there was a clear 
effect on protein expression, with Nanog protein downregulated 8 to 10 hours following 
induction and Sox17 protein beginning to be upregulated around the same time (Fig. 1.8B, 
1.8C). However, the pluripotency marker Esrrb remained detectable (Fig. 1.8B,). Consistent with 
this, qRT-PCR analysis revealed robust induction of FLAG-tagged Gata6 2 hours after  
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doxycycline induction, and greater than 2-fold downregulation of Nanog by 6 hours, followed by 
Sox2 and Esrrb at 8 and 12 hours respectively (Fig 1.8D). Pou5f1 expression was unchanged at 
these early time points (Fig. 1.8D). By contrast, endogenous Gata6 and Gata4 were upregulated 
more than 2-fold relative to uninduced controls within 2 hours of doxycycline induction, 
followed by Sox17 and Pdgfra 4 and 6 hours after induction respectively. 
 
To determine if a short induction pulse was sufficient for lineage commitment, pulse-induced 
cells were returned to pluripotency media for a 48-hour chase period following doxycycline 
withdrawal (Fig. 1.8A). Sox17 expression was detected in the majority of pulse-chase cells 
initially pulsed for 6 hours or longer, suggesting that Gata6 induction had successfully initiated a 
stable endogenous ExEn program by this point (Fig. 1.8C). Consistent with this, flow cytometry 
analysis revealed a gradual reduction of median Nanog expression in pulse-induced cells, 
correlated with increasing length of Gata6 pulse (Fig. 1.E). Similar analysis in pulse-chase cells 
revealed a similar shift (Fig. 1.E), with only a small subset of cells in cultures subjected to pulses 
of 8 hours onwards re-expressing Nanog when returned to pluripotency conditions (Fig. 1.8C, 
1.8E). As heterogeneities in Nanog expression are known to exist within mouse ES cell cultures 
(Chambers et al. 2007; Singh et al. 2007), this likely indicates that these cells have a higher 
threshold of pluripotency gene expression to overcome. Stable iXEN cell lines were successfully 
derived from Gata6 expressing cells induced for 6-12 hours and maintained in the absence of 
doxycycline for more than 10 passages. qRT-PCR analysis confirmed that stable iXEN cells 
maintained ExEn gene expression at levels comparable to eXEN cells, and did not re-express 
pluripotency genes (Fig. 1.9A).  
 
To test the developmental potential of short-pulse iXEN cells, unlabelled iXEN cells were 
injected into B5/EGFP E2.5-3.5 blastocysts that constitutively express enhanced green 
fluorescent protein (EGFP) from a CMV early enhancer/chicken beta actin (CAG) promoter 
(Hadjantonakis et al. 1998). The resulting chimera contribution of incorporated cells was  
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analysed in E3.5-4  blastocysts or E5.5-6.5 post-implantation embryos (Fig. 1.9B, 1.9C, 1.9D). 
Injecting Gata6 12-hour pulse cells gave rise to proportionally fewer E3.5-4 chimera blastocysts 
with exclusive Sox17 expression compared to 12-hour pulse-chase cells (4/32 versus 4/12), and 
the latter also contributed less frequently to Nanog-expressing cells in the embryo (Fig. 1.9B). 
This further suggests that while Gata6 is potent and highly efficient in initiating iXEN cell 
reprogramming, a sufficient interval is required to commit to an ExEn program.  
 
At E3.5-4, injected late passage iXEN cells (greater than P5) contributed predominantly to 
Sox17-expressing primitive endoderm cells in chimera blastocysts (25/38) (Fig. 1.9B). At E5.5-
6.5, late passage iXEN cells contributed to either the extraembryonic visceral or parietal 
endoderm in the majority of chimera embryos (20/24) (Fig. 1.9B, 1.9D). Epiblast contribution 
was not detected (Fig. 1.9B), consistent with previous studies using eXEN cells (Kunath et al. 
2005). Altogether, this demonstrated that short-pulse Gata6 iXEN cells were capable of 
successful ExEn contribution in chimera embryos. However, given that a sufficient interval 
appeared necessary to fully commit to an ExEn program following Gata6 induction, a longer 
induction timecourse was analysed to examine the effect on global transcriptional dynamics. 
 
1.3.2. Gata6 is enriched in regulatory regions of both up- and downregulated genes 
To investigate gene expression dynamics, microarray analysis was performed at defined time 
points from 12 to 144 hours (6 days), as complete downregulation of Nanog, Oct4 and Sox2 was 
previously observed by this timepoint (Fig 1.7C). Samples were compared to uninduced mouse 
ES cells, which reflected the initial pluripotent state, and to eXEN cells, which served as a 
reference for ExEn gene expression. Additionally, Sox7 expressing cells at 144 hours post-
induction (which were not converted to iXEN by this point, as detailed above) were included to 
compare their gene expression to Gata6 induced cells. To determine if Gata6 was directly 
occupying dynamically regulated genes, chromatin immunoprecipitation followed by high-
throughput sequencing (ChIP-seq) analysis of Gata6 binding was carried out after 36 hours of 
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induction, in order to capture both positive and negative gene regulatory dynamics as observed 
in western blot analyses above (Fig. 1.7C).  
 
K-means clustering was performed (Yingying Wei) on the scaled microarray data to group 
differentially expressed genes over the time course into 50 clusters (Fig. 1.10A, Appendix Fig. X1; 
full gene list available in (Wamaitha et al. 2015) Supplemental Table S1). Several functionally 
significant pluripotency-associated genes were rapidly and persistently downregulated within 12 
hours of Gata6 induction including Nanog and Sox2 as previously observed, and Nr5a2, Klf2 and 
Nodal (cluster 25) (Fig. 1.10A). Additional pluripotency genes including Esrrb, Dazl, Dlk1, Ecsit 
and Jarid1b (cluster 29) were more gradually downregulated over time compared to cluster 25. 
Pou5f1, Lefty1, Dppa4 and Dppa2 (cluster 18) were more persistently expressed before eventual 
downregulation, suggesting step-wise downregulation of various nodes of the pluripotency gene 
regulatory network. 
 
Gata6 induction also upregulated several ExEn transcription factors, cell surface proteins and 
basement membrane components in a step-wise manner (Fig. 1.10A). Initial upregulation of 
Gata6, Sox17, Sox7, Foxa1, Foxa2 and Pdgfra (cluster 15) was followed by upregulation of Gata4, 
Hnf1b, Hnf4a and key cell surface and basement membrane components Dab2 and Lama1 
(cluster 39) that are thought to confer an adherence difference to primitive endoderm cells 
(Gerbe et al. 2008; Niakan et al. 2010; Artus et al. 2011). Additional basement membrane 
components and ExEn genes including Lamb2, Col4a1, Cited1 and Braf (cluster 38) were 
upregulated later in the time course (Fig. 1.10A). Key markers of ectodermal (Nestin, Pax6, Sox1, 
Sox3) or mesodermal (Flk1, Hand1, Mixl1, Nkx2.5, T) lineages were not identified within the 
microarray dataset, suggesting that Gata6 specifically induced an endoderm fate.  
 
By contrast, Sox7-induced cells largely retained gene expression patterns similar to mouse ES 
cells. Although Sox7-induced cells upregulated some genes associated with XEN cell function,  
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such as Sall4 (cluster 33) (Lim et al. 2008), they maintained expression of pluripotency factors 
(clusters 18, 25, 29) and did not upregulate endoderm associated genes and basement membrane 
proteins to the same extent as Gata6-induced cells (clusters 15, 38, 39) (Fig. 1.10A). The 
contrasting gene expression dynamics in Gata6- and Sox7-induced cells strongly suggested that 
the potency of Gata6 function might result from binding directly to regulatory regions of both 
up- and downregulated sets of genes to drive this fate switch.  
 
Analysing the ChIP-seq data (Ignacio del Valle) identified 12,632 Gata6 bound regions enriched 
over the input control that were common between three biological replicates, with an FDR of 
<0.01% (full gene list available in (Wamaitha et al. 2015), Supplemental Table S2). De novo motif 
analysis on the top 500 most significant Gata6 bound regions identified the canonical GATA 
motif as most highly enriched (Fig. 1.10B). Gata6 binding <1000bp upstream of gene promoters 
was significantly enriched compared to the whole genome (p-value ≤ 3.7x10-65), in contrast to 
Gata6 binding downstream of genes, which was not significantly different (p-value ≤ 0.277) (Fig. 
1.10C).  
 
Importantly, Gata6 was enriched upstream of genes encoding multiple components of the 
pluripotency regulatory network, such as Esrrb, Lefty1 and Nr5a2, whose expression is 
downregulated during reprogramming (Fig. 1.10D). Gata6 was also enriched at a number of 
rapidly upregulated ExEn associated genes such as Gata4 and Pdgfra (Fig. 1.10D), further 
suggesting that Gata6 directly regulates both pluripotency and ExEn genes. Gata6 was also 
enriched upstream of Fgfr2, suggesting that Gata6 also may be directly regulating FGF signalling.  
 
To relate Gata6 binding to global gene expression dynamics, the ChIP-seq binding data was 
compared to the microarray cluster dataset (Ignacio del Valle) to identify the subset of Gata6-
bound genes that were dynamically regulated over the microarray (full gene list available in 
(Wamaitha et al. 2015), Supplemental Table S3). The comparative analysis revealed a number of 
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Gata6-bound rapidly downregulated genes that clustered with known pluripotency factors, 
suggesting these additional genes may be putative pluripotency factors. One such candidate is 
Etv5 (cluster 25), whose expression has also been associated with mouse ES cells (Zhou et al. 
2007), but whose function has not yet been tested in this context. However, the absence of Gata6 
enrichment near Sox2, whose expression is also rapidly downregulated, may suggest indirect 
repression, possibly due to destabilizing alternative nodes of the pluripotency regulatory 
network. Alternatively, Gata6 may function as a repressor via a binding site located further away. 
Nevertheless, Gata6 appears to regulate a wide variety of genes to drive iXEN reprogramming. 
 
1.3.3. Gata6 shares common gene targets and binding sites with pluripotency factors 
To determine if Gata6 was competing with pluripotency factors for target gene regulation, spatial 
heat map analysis (Ignacio del Valle) was used to compare Gata6 bound loci identified in the 
ChIP-seq analysis to published genome-wide occupancy of Oct4, Sox2, Nanog, Klf4 and Esrrb in 
mouse ES cells (Fig. 1.11A) (Martello et al. 2013). Venn diagrams also illustrate the overlap 
between Gata6-bound and pluripotency factor-bound target genes (Fig. 1.11B). 
 
Gata6-bound loci directly overlapped with 136 Oct4, 190 Nanog, 390 Klf4 and 188 Sox2 gene loci 
(Fig. 1.11A) Intriguingly, some of these sites were present near pluripotency genes including 
Lefty1 (Fig. 1.12), suggesting that Gata6 may directly compete with pluripotency factors to 
antagonize the regulation of some common gene targets. A number of genes, including Nr5a2 
and Esrrb, were bound both by Gata6 and one or more of the pluripotency factors, but at discrete 
loci (Fig. 1.12). Examining the shared gene target dataset ((Wamaitha et al. 2015), Supplemental 
Table S4) revealed that out of 6192 identified Gata6 target genes, 4195 were also targets of Esrrb, 
2815 of Klf4, 1364 of Sox2, 1616 of Nanog and 1104 of Oct4  (Fig. 1.11B), suggesting that Gata6 
may regulate the pluripotency network both directly and indirectly.  
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Several key ExEn genes were included within the list of Gata6 gene targets shared with Esrrb 
including Gata6, Gata4, Sox17, Col4a1, Fgfr2, Pdgfra and Sox7 ((Wamaitha et al. 2015), 
Supplemental Table S4). In contrast, most of these key ExEn genes were not identified among the 
Nanog, Oct4 and Sox2 target gene sets. Previous studies have shown that in addition to its 
function in pluripotent cells downstream of Nanog, Esrrb knockdown or overexpression affects 
endoderm gene expression (Ivanova et al. 2006; Loh et al. 2006; Festuccia et al. 2012; Uranishi et 
al. 2013). However, overexpressing an Esrrb transgene concomitant with doxycycline-induced 
Gata6 expression (Ignacio del Valle) did not prevent downregulation of Nanog expression (Fig. 
1.13A) or subsequent iXEN-like cell differentiation. Moreover, immunofluorescence analysis in 
mouse pre-implantation embryos showed Esrrb and Gata6 expression remained co-incident 
even after downregulation of Nanog in Gata6-high primitive endoderm cells (Fig. 1.13B).  
 
This suggests that perhaps alternative factors may be required in tandem with Esrrb to block the 
endoderm promoting effect of Gata6. Knockdown of additional pluripotency factors such as 
Prdm14 and Nr5a2 has also been shown to upregulate ExEn genes (Ma et al. 2011; McDonald et 
al. 2014) and Gata6-bound loci and gene targets overlapped extensively with those occupied by 
Prdm14 in mouse ES cells (Fig. 1.11A, 1.11B; ((Wamaitha et al. 2015), Supplemental Table S4), 
Consequently, the target gene overlap observed may reflect the dual role of Gata6 and a specific 
pluripotency factor subset in driving their respective cell fates. 
 
Finally, ChIP-seq analysis of Gata6 occupancy in eXEN cells was performed to determine if the 
binding sites identified during Gata6 reprogramming are maintained in this context. Analysing 
the ChIP-seq data (Ignacio del Valle) determined that of the 927 Gata6 gene targets in eXEN 
cells, 504 genes were also targets of Gata6 at the 36-hour post induction timepoint, including 
endoderm target genes such as Gata4, Gata6, Sox7 and Lamc1 ((Wamaitha et al. 2015), 
Supplemental Tables S6 and S7). Interestingly, in the eXEN ChIP-seq, Gata6 binding was not 
detected near many of the pluripotency target genes identified in the induction ChIP-seq, with  
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the notable exception of Nr5a2. This demonstrates that Gata6 binding in eXEN cells is distinct 
compared to cells in transition, and suggests there may not be a requirement for Gata6 to 
actively repress pluripotency factor expression in the long-term after initial downregulation. 
 
1.4. Gata6/GATA6 reprogramming is not restricted to mouse ES cells 
ES cells have a characteristic open chromatin state (Chen and Dent 2014), which may make them 
more amenable to binding of regulatory elements to control gene expression. Consequently, 
Gata6 may have fewer roadblocks to driving reprogramming in this context, as compared to a 
more differentiated cell type with a less accessible genomic landscape. To explore the effect of 
Gata6 induction in a more committed cell type, GATA6 expression was induced in a pure 
culture of a stable neural stem cell line, NS5 (Conti et al. 2005), using the GATA6 lentiviral 
vector previously used to reprogram the ZHBTc4 Oct4 conditional knockout (Fig. 1.4C-F). NS5 
cells had been shown to generate functional neurons that contribute to the adult brain in mouse 
chimeras, without the formation of teratomas (Conti et al. 2005), indicating commitment to their 
specific lineage. The GATA6 construct was transduced into NS5 cells in neural basal media and 
cell identity evaluated 20 days after induction.  
 
Despite retaining a morphological resemblance to neurons (Fig. 1.14A), immunofluorescence 
analysis confirmed that GATA6-transduced NS5 cells robustly induced Gata6, Sox7 and Sox17 
proteins (Fig. 1.14B). Neither untransduced nor GATA6-transduced cells expressed Oct4 and 
Nanog (Fig 1.14B, (Conti et al. 2005). Low levels of Nestin remained detectable in GATA6-
transduced cells (Fig. 1.14B) suggesting that an additional time interval may be required to 
stabilise the XEN cell program and fully overcome the neural stem cell state. Nevertheless, 
conservation of GATA6/Gata6-mediated upregulation of at least some gene targets between 
mouse ES and neural stem cells, despite their distinct supporting gene networks, suggests that 
Gata6 is a powerful lineage specifier. 
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The potency of Gata6 to initiate an ExEn program prompted a final investigation, in a human 
context. Stable XEN cell lines have yet to be established directly from the human PrE, but SOX17 
and GATA6 co-expressing cells can occasionally be observed within human ES and iPS cell 
cultures maintained in pluripotency conditions (Fig. 1.14C). This is reminiscent of the Sox17 
expressing XEN-committed cells observed in mouse ES cell cultures (Niakan et al. 2010) and 
suggests that human ES cells may also have the potential to be converted to XEN cells, perhaps 
by ExEn transcription factor overexpression. Although previous studies overexpressing SOX7 or 
SOX17 in human ES cells report upregulation of either an ExEn or embryonic endoderm 
program respectively, cells retain expression of NANOG and OCT4, and cannot be maintained 
indefinitely in culture (Seguin et al. 2008). To determine if GATA6 expression is sufficient to 
drive iXEN cell reprogramming from human ES cells, a viral GATA6 construct was transduced 
into human ES cells in both pluripotency (mTeSR) and differentiation-permissive (KSR) 
conditions (Ignacio del Valle).  
 
A morphological benchmark for human eXEN cells has yet to be determined. Nevertheless, 
GATA6-transduced human ES cells were morphologically distinct from pluripotent human ES 
cell colonies in both mTeSR and KSR (Fig. 1.14D), suggesting that these cells are beginning to 
acquire an alternative identity. RNA-sequencing analysis was performed to compare the global 
transcriptional profile of GATA6-transduced human ES cells to their untransduced counterparts. 
A principle components analysis (PCA) of genes with the most variable expression revealed that 
GATA6-transduced samples clustered together irrespective of basal media, and were 
transcriptionally distinct from untransduced cells (Fig. 1.14E, Paul Blakeley). This was confirmed 
using hierarchical clustering (Fig. 1.15A, Paul Blakeley). Differential gene expression between 
transduced and untransduced cells was analysed using DESeq (Anders and Huber 2010), an 
extension of the negative binomial distribution model applied to read count data (Robinson and 
Smyth 2008; Robinson et al. 2010) (Fig. 1.15B, Paul Blakeley). 
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Notably, GATA6-transduced human ES cells upregulated a number of extra-embryonic and/or 
pan-endoderm factors including GATA6, GATA4, SOX17, SOX7, FOXA2, PDGFRA, COL4A1, 
COL4A2, LAMA1, HNF4a, DAB2 and SPARC (Fig. 1.15A; 1.15B, (Wamaitha et al. 2015), 
Supplemental Table S7). Significantly, GATA6-transduced cells downregulated the expression of 
several pluripotency factors including NANOG, POU5F1, SOX2, PRDM14, FGF2, FOXD3, 
DPPA4 and ZSCAN10 (Fig. 1.15A, 1.15B; ((Wamaitha et al. 2015), Supplemental Table S7). 
However, GATA6-transduced cells also expressed genes associated with alternative lineages such 
as FLK4, TBX3, CDX2, GATA3, SMAD6, EOMES, HAND1 and TUBB3 (Fig. 1.15A), suggesting 
they may not yet be fully reprogrammed to stable iXEN cells. Moreover, although GATA6-
transduced human ES cells could be clonally passaged more than 3 times and maintained their 
morphology for more than one month, they could not be maintained indefinitely, suggesting 
alternative conditions or factors may be required to derive stable human iXEN cells. 
 
Human ES cells were also transduced with an alternative tetracycline/doxycycline-inducible HA-
tagged GATA6 transgene (Ignacio del Valle). Following doxycycline treatment for 6 days, a 
morphological switch was again observed, and qRT-PCR analysis confirmed the upregulation of 
SOX17, SOX7, FOXA2 and endogenous GATA6 transcripts, and the downregulation of the 
expression of NANOG, SOX2 and POU5F1 (Fig. 1.15C). Immunofluorescence analysis 
confirmed downregulation of OCT4 and NANOG, and upregulation of SOX7, SOX17 and 
GATA4 proteins (Fig. 1.15D), although heterogeneity in endoderm protein induction suggests 
that an additional time interval, culture condition or factor(s) may be needed to generate self-
renewing human iXEN cell lines. Altogether this suggests that GATA6/Gata6 is sufficient to 
overcome a number of distinct cell states to drive iXEN-like cell reprogramming. 
 
1.5. Discussion 
This study finds that Erk2 phosphorylation correlates with nuclear localisation in mouse ES cells, 
therefore observing Erk2 localisation dynamics with the Erk2-Venus fluorescent reporter may be 
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a useful means to investigate FGF/Erk mediated lineage segregation in vivo. Although 
phosphorylated Erk2 does not appear specifically nuclear localised in untreated E3.5 
preimplantation mouse blastocysts, further experiments are necessary to further investigate Erk2 
localisation dynamics over time, especially following FGF signalling modulation. Curiously, 
although serum and LIF are required to maintain mouse ES cell pluripotency, they also stimulate 
Erk phosphorylation in mouse ES cells (Smith et al. 2004). Previous studies demonstrate that 
ERK phosphorylation and nuclear translocation can be sustained or transient depending on the 
stimulus, and downstream outcomes can differ accordingly (Traverse et al. 1992; Adachi et al. 
2002; Costa et al. 2006; Gautier et al. 2011). Thus, although both LIF and FGF stimulate Erk 
phosphorylation, perhaps signalling kinetics or localisation dynamics determine why only FGF-
driven phosphorylation results in differentiation.  
 
This study demonstrates that Gata6 can drive a XEN specification program independently of 
FGF in vitro, and the mechanisms of Gata6-mediated reprogramming may provide insights into 
the genetic hierarchy involved in ExEn development in vivo. In mouse embryos, Gata6 
expression is initiated in the absence of Oct4/Nanog-mediated Fgf4-signalling, but downstream 
Gata4 and Sox17 expression is compromised (Frankenberg et al. 2011; Frum et al. 2013; Kang et 
al. 2013; Le Bin et al. 2014; Schrode et al. 2014). Similarly, FGF signalling is insufficient to drive 
Gata4 and Sox17 expression in Gata6-/- embryos (Schrode et al. 2014). Gata6 binding analysis 
reveals that Gata6 positively regulates itself as well as Fgfr2, Gata4 and Sox17. This suggests that 
although Gata6 is initiated independently in the embryo, it may then require a feedback loop via 
Fgf4/Fgfr2 and Erk signalling to reinforce its own expression to a certain threshold, which 
subsequently triggers the expression of Gata4 and Sox17. 
 
This could also explain the initial co-localization of Nanog and Gata6 in vivo, whereby a 
threshold of Gata6 expression needs to be reached in order to overcome pluripotency. Gata6 
overexpression in vitro likely exceeds this threshold, thereby leading to downregulation of 
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pluripotency and upregulation of ExEn genes, thus allowing iXEN reprogramming to proceed in 
the absence of Fgf4. Inducing high levels of Gata6 expression in the primitive endoderm of Fgf4 
mutant mouse embryos would be one approach to test this hypothesis. Alternatively, Gata6 
levels could be fine-tuned in vitro to determine if Gata6-low Fgf4-/- ES cells fail to induce Gata4 
and Sox17. The doxycycline-inducible transgene system lacks the necessary resolution to address 
this, as titrating the dose of doxycycline has been shown to reduce the penetrance and therefore 
the percentage of cells inducing expression, rather than the quantitative levels within a given cell 
(Beard et al. 2006). 
 
The latent levels of phosphorylated Erk observed across the mouse embryo could also reflect a 
regulatory threshold, as only in cells where Gata6 is independently upregulated will FGF/Erk 
contribute to PrE specification. Intriguingly, ERK phosphorylation sites have been identified on 
the GATA6 protein (Suzuki et al. 1996), and ERK-mediated activation of GATA6 has been 
observed in human colorectal adenocarcinoma cell lines (Adachi et al. 2008), though this is yet to 
be investigated in the mouse embryo. However, as Gata6 can drive iXEN reprogramming in the 
absence of Erk in vitro, this is unlikely to be the only mechanism of Gata6 activation. 
Nevertheless, although they may not exhibit an absolute linear relationship, FGF/Erk signalling 
and Gata6 expression likely eventually converge to bring about PrE specification. 
 
Analysing global Gata6 binding during iXEN reprogramming revealed Gata6 enrichment at both 
pluripotency and endoderm gene targets. Gata6 therefore seemingly functions simultaneously as 
both an activator and repressor of genes during reprogramming, but not necessarily in eXEN 
cells. It has been suggested that other GATA transcription factors, such as Gata1, also have a dual 
activator and repressor role (Yu et al. 2009). However, it is unclear precisely how Gata6 functions 
to regulate both sets of target genes and whether co-factors, chromatin or other epigenetic 
mechanisms may influence this decision. Characterizing sequences surrounding Gata6 bound 
loci may reveal motifs that consistently distinguish Gata6-bound downregulated genes from 
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Gata6-bound upregulated genes. Furthermore, the RNA-guided CRISPR-Cas nuclease system 
(Cong et al. 2013; Mali et al. 2013) could be used to mutagenize Gata6 binding sites, to 
functionally interrogate these putative regulatory loci. 
 
What distinguishes Gata6 from the other endoderm transcription factors tested is the speed with 
which it acts to induce a cell fate switch in the absence of selection. Indeed, most 
reprogramming, including iPS cells, can take several days of selective culture. As the induction of 
Sox17 takes over 2 weeks to downregulate pluripotency (McDonald et al. 2014), this suggests that 
indirect mechanisms eventually lead to XEN conversion, perhaps via Gata6. However, Sox17 has 
been shown to bind to some extraembryonic endoderm genes (Niakan et al. 2010), and thus 
likely directly regulates their expression.  It would therefore be interesting to determine if Sox17 
can induce XEN reprogramming in the absence of Gata6, though seems unlikely given that 
Gata6-/- mouse ES cells fail to initiate cXEN cell conversion in growth factor mediated 
conditions, while Sox17-/- cells generate, but fail to maintain, cXEN cells (Cho et al. 2012). 
 
The Gata6-overexpression system also represents a useful tool to further analyse the functional 
requirement for genes within the ExEn network. A recent study demonstrated that Sox7 
overexpression was insufficient to drive iXEN reprogramming (Kinoshita et al. 2015), consistent 
with the results presented here. Interestingly, Gata6 overexpression in Sox7-/- mouse ES cells was 
sufficient to drive a morphological conversion to XEN-like cells, and lack of Sox7 did not affect 
upregulation of endoderm genes. Moreover, Sox7-/- cells contributed to ExEn-derivatives in 
embryoid bodies (Kinoshita et al. 2015). This would suggest that despite its expression being 
restricted to the PrE (Artus et al. 2011), Sox7 seems dispensable for the establishment of this 
lineage. However, it has been hypothesized that Sox7 and Sox17 have overlapping functions in 
the PrE (Kanai-Azuma et al. 2002; Artus et al. 2011), so Sox17 expression may compensate for 
the lack of Sox7 in this instance.  
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Remarkably, Gata6 drives iXEN cells from mouse neural stem cells, showing that it is a broad 
inducer of reprogramming and can overcome intrinsic programs within distinct cell types. 
However, it would be surprising if all endoderm target genes remained readily accessible for 
Gata6 direct regulation once cells had acquired a neural fate. Therefore, it is possible that Gata6 
may be functioning as a pioneering transcription factor, exposing otherwise closed 
heterochromatic regions as has been shown for FoxA2 and Gata4 (Zaret and Carroll 2011). In 
addition, Gata6 has also been shown to be required for endoderm and mesoderm derived cell 
types (Xin et al. 2006; Tiyaboonchai et al. 2017), so it would be curious to determine whether 
Gata6 overexpression consistently drives one reprogramming outcome. Further characterization 
of Gata6-mediated reprogramming in several cellular contexts would allow interrogation of the 
relationship between transcription factors, signalling and epigenetics in driving cell state 
transitions. 
 
Finally, this study reveals that GATA6 induction can initiate ExEn expression in human ES cells, 
and is also sufficient to inhibit core pluripotency gene expression, distinguishing it from 
previous studies with alternative ExEn transcription factors SOX7 or SOX17 (Seguin et al. 2008). 
It would be interesting to determine if a longer GATA6 induction may be effective in capturing 
stable human iXEN cells, or if alternative conditions may be required. In addition, recent 
transcriptomic analysis of human embryos (Blakeley et al. 2015) may lead to the identification of 
signalling pathways that may be important to stabilize GATA6-induced human XEN cell lines. 
Comparing gene expression in GATA6-transduced cells to expression data from the human PrE 
(Blakeley et al. 2015) and definitive endoderm (Loh et al. 2014) would also be a useful indicator 
as to whether GATA6 is truly driving an ExEn identity.  Altogether this demonstrates that Gata6 
is a versatile and potent reprogramming factor that can act alone to drive a cell fate switch from 
diverse cell types. 
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2. FGF signalling and lineage specification in early human development 
In contrast to its role in promoting differentiation in the mouse Epi and in mouse ES cells, FGF 
is routinely added to maintain human ES cell pluripotency (Thomson et al. 1998; Amit et al. 
2000; Reubinoff et al. 2000; Xu et al. 2001; Cowan et al. 2004; Levenstein et al. 2006; Ludwig et al. 
2006; Chen et al. 2011). Human ES cells also require Activin/Nodal signalling to maintain 
pluripotency and unlike the mouse, are not dependent on LIF or STAT3 (Thomson et al. 1998; 
Daheron et al. 2004; Humphrey et al. 2004; Vallier et al. 2005; Vallier et al. 2009). FGF/MAPK 
inhibition in human ES cells affects Nanog expression and promotes neural differentiation 
(Greber et al. 2010; Greber et al. 2011), which is consistent with a role for FGF in maintaining 
pluripotency.  
 
Curiously, inhibiting MAPK signalling in human blastocysts has no effect on pluripotency (or 
ExEn) gene expression (Kuijk et al. 2012; Roode et al. 2012). Previous studies indicate that FGF 
receptors are not appreciably expressed in the human blastocyst although they are present in 
human ES cells (Dvorak et al. 2005; Kunath et al. 2014); perhaps this differential expression 
explains the contrasting sensitivity to FGF signal modulation. Alternatively, FGF may function 
via an Erk-independent pathway in the human embryo.  
 
Only a few studies thus far have interrogated signalling in the human embryo, likely partly due 
to the relative scarcity of embryos surplus to family building via IVF that are available for 
research. The initial investigations that established the conditions for human ES cell derivation 
were carried out in non-human primates (Thomson et al. 1995; Thomson et al. 1996), and may 
not necessarily reflect the requirements of early human embryonic development. Consequently, 
modulating signalling and analysing gene expression patterns in the human Epi directly would 
help clarify the role of FGF in the embryo and shed light on these incongruities. 
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Therefore, in this chapter, I investigate the effect of stimulating FGF signalling during early 
human embryonic development, and also explore whether additional alternative signalling 
pathways are required to maintain the human Epi. 
 
2.1. Exploring FGF signalling in the human embryo 
The incongruous effects of FGF signalling modulation in the human blastocyst and ES cells 
imply that there may be distinct pathway components acting in these contexts. Our lab has 
recently compiled a single cell transcriptomic dataset from human embryos at multiple 
developmental stages (1-cell zygote to blastocyst), collating newly collected samples and data 
from a recently published study (Yan et al. 2013; Blakeley et al. 2015). Therefore, this dataset 
represented a useful resource for exploring human blastocyst-specific signalling pathways. In 
addition, data from single cell analysis of human ES cells was also collated for comparison with 
the Epi compartment. 
 
Paul Blakeley performed analysis of the sequencing data. Briefly, the reads per kilobase of exon 
model per million mapped reads (RPKM) method (Mortazavi et al. 2008) was used to normalize 
for sequencing depth and transcript length. The threshold of significance was set at >5 RPKM for 
median gene expression, which has been shown to reliably capture functional mRNA expression 
(Hebenstreit et al. 2011). To investigate differences in global gene expression, a PCA of the top 
8000 genes with the most variable expression was performed on the human late blastocyst 
samples, which clustered into 3 groups (Blakeley et al. 2015). Cells were then segregated into Epi, 
PrE or TE depending on enrichment of lineage-associated genes in each cluster, as determined 
by two independent analyses, NOISeq and DESeq (Anders and Huber 2010; Tarazona et al. 
2011). Considerable overlap was observed in the genes predicted by these two independent 
statistical methods (Blakeley et al. 2015), lending confidence to the resulting lineage assignations. 
Finally, boxplots of RPKM values were generated to show the range of gene expression in human 
ES cells and the blastocyst samples.  
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2.1.1. FGF signalling-related transcripts are differentially expressed in existing human 
ES cells and human blastocysts 
Interrogating the RPKM boxplot dataset identified a number of differences in FGF receptor and 
ligand transcript expression between the various cell types. FGFR1 was expressed in both the Epi 
and human ES cells, but most enriched in the PrE, while FGFR2 was expressed only just above 
the >5 RPKM significance threshold in human ES cells, the Epi and PrE, and not significantly in 
the TE (Figure 2.1A). In contrast, FGFR3 and FGFR4 median expression fell below the >5 RPKM 
significance threshold in both human ES cells and the Epi, and the receptors were respectively 
more abundant in the PrE, or both PrE and TE (Figure 2.1A).  
 
Previous studies suggesting that FGF receptors are not appreciably expressed in the human 
blastocyst had analysed receptor expression in whole blastocysts via RT-PCR (Kunath et al. 
2014). The boxplot dataset indicates FGFR1 is most enriched in the PrE, which makes up a 
relatively small proportion of the embryo in the late blastocysts analysed here, therefore perhaps 
single cell analysis allows for greater resolution by compensating for an overabundance of non-
expressing cells in whole-blastocyst samples. Furthermore, FGFR1 protein has been detected in 
the human embryo (Niakan and Eggan 2013), with an initially broad expression pattern that 
becomes restricted to a few cells at later stages. FGF2 ligand transcripts were not appreciably 
expressed in the epiblast, while median FGF4 expression was below 5 RPKM (Figure 2.1B). In 
contrast, only FGF2 was appreciably expressed in human ES cells. A number of additional FGF 
ligands were also detected, mainly in human ES cells (Figure 2.1B).  
 
Analysing downstream kinase expression in the single cell dataset revealed expression of MAPK 
signalling components across all the blastocyst lineages, including MAP2K1 (MEK1) and 
MAPK1 (ERK2) (Figure 2.2A). Interestingly, the Ras gene ERAS, a novel MAPK signalling 
component thought to promote growth in mouse ES cells (Takahashi et al. 2003) was not 
appreciably expressed in human ES cells or the epiblast. There appeared to be no preferential  
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enrichment compared to other lineages that would suggest a requirement for FGF signalling in 
the Epi or human ES cells. If FGF does indeed function via a distinct pathway in the embryo, one 
potential alternative is the phosphatidylinositol 3-kinase (PI3K) pathway, which has been 
implicated in mouse ES cell self-renewal (Burdon et al. 1999; Paling et al. 2004). A number of 
PI3K signalling kinases were also detected in the human blastocyst (Figure 2.2B). In all, there 
appeared to be evidence for a capability for FGF signal transduction within the embryo, at least 
based on transcript availability. Therefore, experiments were set up to treat human embryos with 
exogenous FGF and determine the effect on lineage segregation. 
 
2.1.2. FGF stimulation does not enhance the pluripotent epiblast 
Previous experiments in mouse embryos had identified a dose-dependent effect of FGF 
stimulation on cells within the ICM (Yamanaka et al. 2010). FGF treatment resulted in a cell fate 
conversion of Nanog-expressing Epi cells to Gata6-expressing PrE cells, with doses from 250 ng 
to 1 µg/ml FGF supplemented with 1 µg/ml heparin converting all cells in the E4.5 mouse ICM 
to PrE (Yamanaka et al. 2010). Therefore, a similar treatment schedule was set up with human 
embryos to investigate the effect of FGF stimulation (Figure 2.3A); if FGF was required for 
pluripotency expression, the converse effect should be observed. 
 
8-cell human embryos (E2.5) were first cultured in media supplemented with 1 µg/ml FGF2 and 
1 µg/ml heparin (Figure 2.3B), similar to the mouse embryo experiments. By E6.5, untreated 
control embryos formed an expanded blastocyst and expressed both NANOG and GATA6 
(Figure 2.3B). In contrast, FGF-treated embryos did not express NANOG and appeared smaller 
compared to sibling-matched controls, suggesting they may be developmentally delayed (Figure 
2.3B). Additionally, cellular debris was observed within some embryos (arrows), perhaps 
indicative of apoptotic cells (Figure 2.3B). This differs from FGF-treated mouse embryos, which 
appear developmentally normal despite lineage conversion within the ICM (Yamanaka et al. 
2010). 
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Embryos were next treated with 100 ng/ml FGF2, a concentration commonly used to maintain 
human ES cell pluripotency in vitro (Ludwig et al. 2006), and thus possibly more relevant in a 
human context. Again, by E6.5 treated embryos lacked NANOG-expressing cells but retained 
GATA6-expressing cells, with indications of potentially apoptosed cells (Figure 2.3C). 
Furthermore, although these embryos still expressed the TE marker CDX2, there appeared to be 
unusually extensive co-localisation of CDX2 and the PrE marker SOX17 (Figure 2.3D), which 
suggests there may also be an effect on these lineages despite the continued expression of key 
lineage markers. However, FGF might instead be required for maintenance of the epiblast once 
established, promoting proliferation or survival for example, and perhaps the observed adverse 
effect resulted from FGF exposure at a premature developmental stage.  
 
To investigate this, embryos were treated with 100 ng/ml FGF2 from E6, by which time NANOG 
and OCT expression is restricted to the ICM (Niakan and Eggan 2013). Treated embryos 
appeared developmentally normal and NANOG expression was detected in the ICM (Figure 
2.3E). To determine whether the proportion of NANOG-expressing cells was affected, the 
automated software tool MINS 1.3 (Lou et al. 2014) was used to detect and segment DAPI-
stained nuclei. The number of NANOG- or SOX-17 expressing cells was then calculated as a 
proportion of the total cells in the embryo, and treated embryos then compared to controls to 
determine any statistically significant changes in proportion. Although the proportion of 
NANOG- or SOX17-expressing cells in FGF-treated embryos initially appeared lower than 
expected, values were within the range of controls (Figure 2.3F), and further embryos are being 
analysed to confirm this. Altogether, this suggests that in contrast to its pluripotency 
maintenance function in human ES cells, FGF is detrimental to the establishment of the 
pluripotent epiblast compartment in vivo.  Treatment at later stages, while no longer detrimental, 
does not seem to have a detectable effect on lineage proportions within the blastocyst. This 
implies that rather than operating via an alternative pathway in the human embryo, FGF is 
unlikely to be required at all. 
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2.2. Characterising gene expression in the human Epi 
It is increasingly apparent that existing human ES cells are generally distinct from the human Epi 
in terms of their gene expression patterns (Blakeley et al. 2015), and the discrepancies observed 
with FGF treatment seemingly support this. Therefore, analysing differential gene expression 
between lineages in the human blastocyst could reveal key pathways that could then be 
manipulated to investigate how the Epi is established and maintained. Furthermore, modulating 
these pathways to adapt existing human ES cells and for new derivations could define culture 
conditions to support human ES cells that were more similar to, and thus a better model for, the 
originating human Epi compartment.  
 
To interrogate lineage-specific gene expression patterns in the human blastocyst, the DESeq 
differential gene expression dataset (Blakeley et al. 2015) was used. Comparing genes enriched in 
the human Epi vs. TE, and Epi vs. PrE, identified classic factors such as NANOG and SOX2 
enriched in the Epi, CDX2 and GATA3 in the TE, and GATA4 and SOX17 in the PrE (Figure 
2.4A). Several additional genes were identified as enriched in each lineage, such as ESRG 
(HESRG), which has been signposted as a putative pluripotency gene (Zhao et al. 2007; Li et al. 
2013). The Kruppel-like factor family member KLF17 (van Vliet et al. 2006) was also identified as 
enriched in the Epi (Figure 2.4A), and boxplot RPKM data revealed it was exclusive to this 
lineage (Blakeley et al. 2015). If these novel factors also segregated with known lineage-associated 
genes at the protein level, it would validate the ability of the transcriptomic analysis to predict 
novel lineage-associated factors. Immunofluorescence staining confirmed that KLF17 protein 
expression was also restricted to the human Epi, and was coincident with NANOG (Blakeley et 
al. 2015). Furthermore, the human PrE-specific transcript FOXA2 was also validated at the 
protein level (Blakeley et al. 2015), although it is only associated with later stage endoderm in the 
mouse (Kimura-Yoshida et al. 2007). Consequently, the differential expression transcriptome 
dataset appeared to be a valid predictive tool. 
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DESeq analysis identified a number of TGFβ/Nodal signalling-associated genes as enriched in 
the Epi, including the ligands NODAL and GDF3, the EGF-CFC co-receptor TDGF1 (prior 
annotation CRIPTO), and the antagonists LEFTY1 and BAMBI (Fig. 2.4A, 2.4B). Additional 
TGFβ signalling pathway components were present in the Epi above the RPKM >5 significance 
threshold, but were not differentially expressed as they were also expressed in the TE (Fig. 2.4B; 
(Blakeley et al. 2015). However, distinct upstream components TGFRB1 and SMAD5 were 
enriched in the TE (Fig. 2.4A, 2.4B), which are instead involved in negative regulation of the 
pathway, suggesting that TGFβ/Nodal is differentially activated in the Epi compared to the TE. 
In addition, the insulin/IGF1 signalling pathway ligand IGF1 was identified as enriched in the 
PrE, while the IL6R receptor subunit IL6R, which can also bind insulin ligands ,  was enriched in 
the Epi (Fig. 2.4A).  
 
To identify putative signalling pathways on a wider scale, the GOrilla gene ontology (GO) 
analysis tool (Eden et al. 2007; Eden et al. 2009) was used to mine the dataset of genes expressed 
>5 RPKM in half or more of the Epi cells analysed. This would allow for inclusion of 
downstream pathway components that may be present in the Epi but not necessarily be 
differentially expressed. A number of signalling related categories were identified, with several 
linked to regulation of Wnt and TGFβ signalling (Appendix Table X1). Analysing the equivalent 
TE dataset also pulled out TGFβ signalling related terms, consistent with the DESeq data above 
(Appendix Table X2), as well as several Wnt related terms. This may indicate why modulating 
Wnt signalling in existing human ES cells has alternately been found to promote either 
pluripotency or differentiation (Sato et al. 2004; Davidson et al. 2012). 
 
Both TGFβ/Nodal and insulin/IGF1 pathways have been previously implicated in either human 
or mouse ES cell culture systems. TGFβ/Nodal signalling has been shown to regulate 
pluripotency gene expression and is routinely used to maintain human ES cells (Amit et al. 2004; 
Vallier et al. 2004; Vallier et al. 2005; Brown et al. 2011). Addition of the TGFβ family ligand 
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Activin A is also sufficient to maintain human ES cell pluripotency and Activin is expressed and 
secreted by the MEF layer used in classical human ES cell culture (Beattie et al. 2005; James et al. 
2005; Vallier et al. 2005). Nodal-overexpressing cells can also be maintained in chemically 
defined medium (CDM) without FGF or serum (Vallier et al. 2004). Culture in Activin alone 
supported more OCT4-positive colonies than Nodal alone, though FGF supplementation in 
tandem with NODAL rescued this deficit. However, higher doses of Nodal can dispense with 
FGF entirely (Vallier et al. 2005). 
 
Insulin/IGF1 signalling has been implicated in self-renewal in alternative contexts 
(Malaguarnera and Belfiore 2014), and may also have a role in maintaining human ES cells 
(Bendall et al. 2007; Wang et al. 2007). Revisiting the boxplot RPKM dataset revealed that neither 
IGF2 nor insulin (INS) ligands are detectable in either the blastocyst or human ES cells (Fig. 
2.4C), but IGF1 is indeed enriched in the PrE (Fig. 2.4C), as indicated in the DESeq analysis. 
IGF1R was expressed in human ES cells but fell below the 5 RPKM significance threshold in the 
blastocyst lineages, while the insulin receptor (INSR) was detected in the Epi and in human ES 
cells (Fig. 2.4C). IGF2R was detected at below threshold levels in both human ES cells and the 
blastocyst lineages.  
 
In addition, the interleukin-6 receptor IL6R, shown to crosstalk with insulin/IGF1 signalling in 
an alternative context (Abroun et al. 2004), was highly enriched in both the Epi and PrE, while 
its co-receptor IL6ST (formerly GP130) was present in the PrE, and just below the threshold in 
the Epi. Altogether, this suggests a possible role for the insulin/IGF1-signalling pathway in the 
Epi and PrE lineages, though it is unclear what effect if any this may have in terms of lineage 
determination. Therefore, the TGFβ/Nodal and insulin/IGF1 signalling pathways seemed ideal 
starting points for signalling modulation in the human blastocyst.  
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2.2.1. IGF treatment promotes proliferation within the human ICM 
In addition to its proposed role in human ES cell maintenance (Bendall et al. 2007), insulin/IGF1 
signalling has also been implicated in embryo development. Previous studies suggest that IGF1 
may be present in the Fallopian tube and uterine fluid (Lighten et al. 1997; Lighten et al. 1998), 
and studies treating human embryos with IGF1 identified an increase in proportion of embryos 
developing to the blastocyst stage, as well as an increase in the number of cells in the ICM 
compartment (Lighten et al. 1998; Spanos et al. 2000). Similar effects had been observed in 
mouse embryos in earlier experiments (Harvey and Kaye 1992). However, these studies did not 
distinguish between Epi and PrE cells within the ICM. 
 
Putative treatment factor concentrations were initially tested on 4 – 8-cell mouse embryos to 
determine toxicity, as measured by the number of treated embryos developing to the blastocyst 
stage relative to controls. If concentrations were deemed non-toxic, human embryos were then 
cultured from either E2.5 (cleavage) or E5 (early blastocyst) till E6-7 (late blastocyst) (Fig. 2.5A). 
Treated and control embryos were stained for NANOG and SOX17 to mark Epi and PrE lineages 
respectively, and thus determine whether a given treatment affected a particular ICM lineage or 
induced a cell fate switch. NANOG and SOX17 were chosen as they are well-established markers 
of these two lineages, but in future newly identified human-specific factors such as KLF17 and 
FOXA2 (Blakeley et al. 2015) may be additional factors to consider. The proportions of Epi and 
PrE cells were quantified using the MINS software tool. 
 
8-cell human embryos (E2.5) were first treated with 1.7 nM IGF1, the concentration found to 
affect ICM cell number in earlier studies (Lighten et al. 1998). By E6.5, treated embryos had 
formed an expanded blastocyst and expressed both NANOG and SOX17 (Fig 2.5B). MINS 
analysis identified a slight increase in the proportion of NANOG-expressing cells, although this 
was not significantly different compared to controls (Fig 2.5C, 2.5D), while the proportion of 
SOX17-expressing cells had significantly increased (Fig 2.5C, 2.5D). The total number of ICM  
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cells had indeed increased slightly relative to controls, though there was no difference in total 
number of cells in the embryo (Fig 2.5C, 2.5D), consistent with previous work (Lighten et al. 
1998). 
 
Embryos were next treated with a 10-fold higher IGF1 concentration to determine if a 
dose-response effect could be observed. At E6.5, embryos treated with 17 nM IGF1 had 
significantly increased proportions of both NANOG- and SOX17-expressing cells (Fig 2.5B, 
2.5C, 2.5D), and total ICM cell number was again slightly increased (Fig 2.6C, 2.6D). Embryos 
were then treated with 17 nM IGF1 from E5, to determine if this effect was conserved with IGF1 
exposure at the later stage. However, in these later-stage embryos proportions of both NANOG- 
and SOX17-expressing cells, and total ICM cell number, remained equivalent to controls (Fig 
2.6C, 2.6D), suggesting a longer exposure coupled with higher dosage is required for this effect. 
 
While calculating the proportion data, it was noted that there were significantly fewer total cells 
in the embryos treated with 17 nM from E2.5 (Fig 2.5D). Although this may indicate that the 
expansion of the ICM is occurring at the expense of the TE, it may also reflect an unavoidable 
element of human embryo culture. Even though embryos were selected from the same 
developmental stage and treated for the same temporal period after thawing, human embryos are 
frozen at differing times and thus develop according to slightly different timetables. To 
determine whether this may explain the lower total cell number, the Gardner and Schoolcraft 
embryo grading scale (Gardner and Schoolcraft 1999) was used to assess both treated and 
control embryos.  
 
Grading revealed that when collected for analysis, more embryos in the control and 1.7 nM 
datasets were fully hatched (grade 6), or hatching (grade 5), from the zona compared to embryos 
treated with 17 nM, which were mainly full (grade 3) or expanded (grade 4) (Fig 2.6A). Given the 
small sample size, this difference would likely have a greater impact on analysis. Increasing the  
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number of both control and treated embryos would determine if there are consistently more 
expanded embryos in control embryos, which may indicate a TE-specific effect of IGF treatment. 
In addition, a larger pool would hopefully encompass embryos at various expansion stages, 
ideally with a great enough number to allow for binning according to grade and subsequent 
comparisons without loss of statistical power. Furthermore, analysing TE protein expression 
would elucidate whether this lineage is being appropriately specified. 
  
Finally, examining the rates of blastocyst development between treated and control embryos 
indicated that IGF1 exposure at 1.7 nM doubled the number of E2.5 blastocysts that successfully 
formed blastocysts (Fig 2.6B). This effect was not observed at the higher concentration of IGF1 
(Fig 2.6B). This may be especially relative in an IVF context, where lower rates of embryo 
progression to blastocyst compared to mouse embryo culture may reflect a sub-optimal, though 
reasonably adequate, human embryo culture environment. Furthermore, it has been 
hypothesised that larger ICMs positively correlate with implantation rates following blastocyst 
transfer (Richter et al. 2001; Lagalla et al. 2015). In all, IGF1 treatment has a demonstrable 
proliferative effect in the human embryo, specifically in the ICM, and may also positively 
promote embryo survival in vitro. 
 
2.2.2. Nodal signalling is required to maintain the pluripotent epiblast 
To investigate whether TGFβ/Nodal signalling is active during early human development, 
embryos were first treated (Norah Fogarty) with SB-431542 (SB), a potent inhibitor of 
TGFβ/Activin-induced Smad2 phosphorylation that had been shown to reduce NANOG 
expression in human ES cells (Callahan et al. 2002; Inman et al. 2002; Greber et al. 2010; Blakeley 
et al. 2015). Embryos were cultured with 40 µM SB, a concentration shown to be non-toxic and 
effective at blocking Nodal signalling in peri-implantation mouse embryos (Granier et al. 2011). 
In comparison, SB-treated pre-implantation mouse embryos retained Nanog expression 
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(Blakeley et al. 2015), consistent with the lack of enrichment for Nodal transcripts in the 
preimplantation mouse blastocyst.   
 
At E6.5, the majority of human embryos treated with SB had lost NANOG expression, though 
they retained expression of SOX17 (Fig. 2.7B; (Blakeley et al. 2015)). Assessing whether the 
proportion of SOX17 cells remained unchanged was complicated by the lower levels of SOX17 
detected in the majority of treated embryos (Blakeley et al. 2015). However, where SOX17 
expression was detectable and quantifiable, the proportion of SOX17 cells was within the range 
of controls (Fig. 2.7C), suggesting that SB treatment destabilised NANOG expression in Epi cells 
but did not convert these cells to PrE. Therefore, this strongly suggests that Nodal signalling is 
essential for pluripotency in the human EPI. Curiously, previous experiments modulating 
TGFβ/Nodal signalling with SB instead observed a positive effect on NANOG expression and 
subsequent human ES cell derivation (Van der Jeught et al. 2013). However, a four-fold lower 
concentration of SB was used, and derivations were carried out on a supportive MEF layer (and 
thus in the presence of secreted Activin, (Greber et al. 2010), suggesting TGFβ/Nodal signalling 
may not be fully suppressed. 
 
To test whether exogenous TGFβ/Nodal signalling could drive a lineage switch within the 
human embryo, similar to FGF signalling modulation in the mouse, blastocysts were treated with 
the TGFβ family ligand Activin A. Embryos were first treated with 10 ng/ml recombinant 
human Activin, a concentration commonly used to maintain human ES cell pluripotency 
(Vallier et al. 2005). E.5 blastocysts treated with 10 ng/ml Activin for 2 days expressed both 
NANOG and SOX17, in proportions similar to control embryos (Fig. 2.7B, 2.7C), suggesting that 
Activin may not be effective at this concentration in vivo.   
 
Embryos were next treated with 50 ng/ml Activin, a concentration previously used to treat 
human embryos (Van der Jeught et al. 2013). Although the proportion of NANOG-expressing  
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cells was again within range of controls, no SOX17 expression was observed in some embryos 
(Fig. 2.7B, 2.7C), suggesting Activin may instead be negatively affecting the PrE. Experiments are 
underway to confirm this, both increasing sample sizes under the conditions reported, but also 
treating embryos with Activin from earlier stages (E2.5) to determine if there is a greater effect, 
as was observed in the IGF1 study. Altogether, this shows that although Nodal signalling is 
required to maintain NANOG expression in the human Epi, endogenous levels are likely 
sufficient for this to occur, and further stimulation at the blastocyst stage does not affect the 
proportions of pluripotent cells. However, there is an indication that Activin/Nodal signalling 
may negatively affect gene expression in the PrE, and it will be interesting to determine if this 
holds true following further experiments.  
 
2.2.3. Laminin-specific integrins are expressed in the human embryo  
Initial human ES cell derivation and culture systems relied on a supportive MEF layer and the 
addition of serum or Knockout Serum Replacer as a means to preserve pluripotency in vitro 
(Thomson et al. 1998). However, the undefined nature of this culture system allowed for the 
presence of confounding factors that may instead antagonise the pluripotency support network. 
Supporting matrix substrate layers are commonly used in place of feeders, such as Matrigel, 
which consists mainly of laminin, though additional factors such as collagen and nidogen are 
also present (Kleinman et al. 1982). However, Matrigel is distilled from Engelbreth-Holm-Swarm 
(EHS) sarcoma cells and thus remains subject to batch-to-batch variability, and even in its 
growth factor-reduced form retains noticeable concentrations of various growth factors, 
including FGF (BD-Biosciences). 
 
The basement membrane factors that constitute Matrigel, such as laminin and collagen, have 
also individually been used to support growth of human ES cells, and similar to others such as 
fibronectin and vitronectin, have also been included in various minimal media culture systems 
(Ludwig et al. 2006; Chen et al. 2011; Rodin et al. 2014; Takashima et al. 2014). Ideally, the 
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chosen basement membrane used in vitro would recapitulate binding profiles in the embryo, 
preferentially Epi-Epi to maintain the characteristics of the original niche, but also perhaps Epi-
PE or Epi-TE. Once again, the human blastocyst gene expression dataset provides a valuable 
resource to investigate embryo-specific basement membrane components, at least at the 
transcript level, which could then be validated experimentally.  
 
The RPKM boxplot dataset was used to explore the expression of integrin subunits, in order to 
determine whether any known integrin binding partners for commonly used basement 
membrane proteins (Humphries et al. 2006; Campbell and Humphries 2011) were enriched in 
the embryo. Transcripts for several integrins were identified (Fig 2.8A), with those representing 
the laminin-binding integrin α6β1 (ITGA6, ITGB1) enriched in both human ES cells and the 
blastocyst lineages (Fig 2.8A). Additional subunits ITGA5 and ITGAV were detected in human 
ES cells, though expression fell below the significance threshold (Fig 2.8A). ITGA5 and ITGAV 
can complex with ITGB1 as integrin α5β1and αVβ1receptors, which bind fibronectin and 
vitronectin respectively (Humphries et al. 2006; Campbell and Humphries 2011) This varied 
integrin profile may explain why existing human ES cells can be supported by multiple basement 
membranes. Previous studies have shown that integrin α6β1 preferentially binds laminin-111, 
laminin-511 and laminin-521 (Nishiuchi et al. 2006; Miyazaki et al. 2012; Nakagawa et al. 2014), 
and therefore the expression pattern of the transcripts associated with these laminins was also 
determined (Fig 2.8A). Transcripts for laminin-111 (LAMA1, LAMB1, LAMC1) were enriched 
across all blastocyst lineages and in human ES cells, as was the LAMA5 subunit, though the latter 
fell just below the significance threshold (Fig 2.8A). Previous studies have demonstrated 
successful growth of human ES cells on laminins (Xu et al. 2001; Miyazaki et al. 2012), and 
laminin protein expression has been observed in both human ES cells and MEFs (Hongisto et al. 
2012; Pook et al. 2015).  
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Whole recombinant human laminin-511 (Biolamina, (Rodin et al. 2014)) and a recombinant 
Laminin-511 E8 fragment (iMatrix-511, Takara (Nakagawa et al. 2014)), were evaluated for their 
ability to maintain human ES cell pluripotency. Consistent with previous studies, both H1 and 
H9 human ES cell lines could be maintained on laminin in mTeSR media, as were maintained 
for multiple passages without losing ES cell morphology (Fig 2.8D). Although pluripotency gene 
expression is yet to be determined, previous work has demonstrated that laminin maintains 
OCT4 and NANOG gene expression in human ES cells, comparable to Matrigel (Takashima et 
al. 2014). Consequently, laminin appears to be a suitable embryo-specific basement membrane 
substrate capable of supporting existing human ES cells, and potentially deriving new ones. This 
is promising for future experiments that would seek to integrate signalling insights from the 
human blastocyst to design minimal chemically defined stem cell culture conditions that would 
better recapitulate the pluripotent niche. 
 
2.3. Discussion 
Although earlier studies indicated that inhibiting FGF/Erk signalling had no effect in the human 
embryo (Kuijk et al. 2012; Roode et al. 2012), they did not rule out the possibility of FGF 
functioning via an alternative downstream pathway as the FGF receptor was never targeted 
without also inhibiting Mek (Roode et al. 2012). This study finds that despite expression of FGF 
signalling pathway components in the human blastocyst, FGF stimulation negatively affects 
establishment of the pluripotent Epi and appears dispensable for maintenance. This is at odds 
with long-established human ES cell derivation and culture conditions, and challenges 
predominant assumptions about the signalling pathways regulating this lineage.  
 
It is unclear why existing human ES cells are reliant on FGF signalling for their maintenance, as 
Activin/Nodal signalling seems to be the main pathway required to regulate pluripotency gene 
expression (Vallier et al. 2004; Vallier et al. 2005; Vallier et al. 2009). However, previous studies 
reported that treatment with the MEK inhibitor PD0325901 resulted in downregulation of 
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NANOG expression in human ES cells by 50% within 12 hours (Greber et al. 2010). Although 
treatment with SB-431542 resulted in greater NANOG downregulation over the same time 
period (85%), there were indications of a synergistic effect when both inhibitors were added 
(Greber et al. 2010), suggesting cooperative regulation of pluripotency by FGF and 
Activin/Nodal signalling, as previously reported (Vallier et al. 2005). As classical human ES cell 
derivation conditions involved addition of exogenous FGF, this may have promoted an in vitro 
adaptation of these cells towards FGF-dependency, perhaps as a substitute for an alternative 
ligand with similar downstream effects. Altogether, this further reinforces the finding that 
current human ES cells are distinct from the epiblast progenitors from which they are derived 
(Blakeley et al. 2015).  
 
With this in mind, it seemed appropriate to take an unbiased approach and interrogate lineage-
specific gene expression patterns in the human blastocyst directly. This study demonstrates that 
inhibiting TGFβ/Nodal signalling detrimentally affects NANOG expression, although 
supplementation with Activin does not seem to enhance the pluripotent compartment (though it 
may negatively affect gene expression in the PrE). This would seemingly suggest that 
endogenous NODAL signalling is sufficient to maintain the Epi in vivo, though further 
experiments treating human embryos with Activin from an earlier developmental stage, prior to 
epiblast maintenance, should shed further light on this. 
  
How does this fit into the narrative of existing stem cell derivation and human ES cell 
maintenance, where Activin/Nodal signalling has been shown to regulate pluripotency gene 
expression? Perhaps exogenous Activin confers a greater benefit in vitro due to the lack of some 
other factor that would normally boost pluripotency, and whose absence is preventing human ES 
cells from secreting sufficient Nodal to support their continued self-renewal. Alternatively, a 
higher dose of Activin may be required to antagonise differentiation-promoting influences in 
culture, such as FGF for example, or BMP, which is present in serum (Ying et al. 2008), and has 
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been shown to destabilise pluripotency (Xu et al. 2002; Pera et al. 2004; Valera et al. 2010). In 
addition, although Nodal and Activin have been demonstrated to act equivalently in human ES 
cells, it is possible that Nodal may have a distinct effect in the human blastocyst. Activin 
transcripts (INHBA and INHBB) are not enriched in the human blastocyst, and given the 
distinctions emerging between human ES cells and the Epi compartment, it would be prudent to 
test the role of Nodal in vivo as well. 
 
Remarkably, IGF signalling increases the proportion of both NANOG- and SOX17-expressing 
cells in the human ICM, suggesting this perhaps feeds into the proliferation and self-renewal 
circuitry of these lineages. Characterising global gene expression in IGF1-treated embryos and 
perhaps integrating this data into the single cell blastocyst dataset will be useful to determine the 
mechanics of this effect. A number of existing human ES culture media, supplements and 
basement membrane substrates contain IGF1 or insulin, including Knockout Serum 
Replacement (KOSR), N2B27, mTeSR and TeSR-E8, StemPro and Matrigel (BD-Biosciences ; 
Price et al. 1998; Ludwig et al. 2006; Wang et al. 2007; Chen et al. 2011; Ying and Smith 2012), 
suggesting this pathway may be unwittingly already supporting self-renewal. It would be 
interesting to determine if the proliferation effect in the embryo is specific to IGF1, or whether 
additional insulin/IGF1 signalling pathway ligands such as insulin or IGF2 may be capable of 
replicating this phenomenon. 
 
Altogether, the transcriptomics dataset has been a useful window into human-specific gene 
expression. However, although initial steps are encouraging, with roles for insulin/IGF1 and 
TGFβ/Nodal signalling emerging with the human embryo, it still remains unclear what signals 
are responsible for specifying the Epi and PrE lineages within the human blastocyst. A caveat of 
the current analysis is that interrogating gene expression in the late blastocyst may be too late to 
identify signals required for specification, which may have been set in motion well before. 
Perhaps analysing the wider single cell dataset from earlier developmental stages may yield 
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results in this regard. Nevertheless, in the face of increasing divergence from both mouse 
embryonic developmental models and current human ES cells, the early human embryo 
represents a crucial system for investigating the fundamental biological mechanisms underlying 
cell fate choices. 
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Conclusions 
 
The differences emerging between mouse and human gene expression in early development 
highlight the importance of further investigations in a human context. The human Epi seemingly 
does not depend on the same signalling pathways as the mouse – no reliance on LIF, no 
requirement for BMP/Id proteins to cooperate with STAT3 or antagonise FGF, which would 
otherwise promote differentiation. This raises interesting questions as to how lineage 
specification takes place in the human embryo, which this study attempted to address by 
investigating enrichment of signalling networks in single cells isolated at the blastocyst stage. 
One caveat of the dataset described here is that only one timepoint was explored, and at this 
stage cells could already be resolved into definitive lineages. Consequently, it is likely not 
possible to distinguish between lineage-specifying and lineage-maintenance networks, assuming 
that the mechanisms responsible for specification are set in motion earlier in development. 
However, this may be less of a concern if lineage segregation in the human does not follow the 
two-step mouse model of early ICM-TE segregation followed by later Epi-PE segregation within 
the ICM, as recent transcriptomic analysis suggests (Petropoulos et al. 2016). Cells in the early 
human embryo seem to retain developmental plasticity for longer than the mouse, though it is 
not clear why this is the case – one hypothesis is that the shorter developmental timeline in the 
mouse necessitates earlier lineage segregation (Rossant 2014), ensuring a fully committed TE is 
present in time for appropriate implantation to occur. 
 
Nevertheless, the loss of NANOG expression observed here following TGFβ/Nodal signalling 
inhibition suggests this pathway feeds into the pluripotency gene regulatory network in vivo, as it 
does in existing human ES cells. Similarly, the ICM proliferation observed following 
insulin/IGF1 signalling activation suggests this pathway may feed into a self-renewal circuitry in 
vivo that is then perpetuated to allow derivation of ES cells, thereby capturing this otherwise 
transient population. Given that increased numbers of both NANOG- and SOX17-expressing 
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cells are observed following IGF1 treatment, it is unlikely to function via an Epi-specific 
mechanism, but could shed light on segregation of the ICM and the TE, as the TE appears 
unaffected. Although the current sample size is small, this hypothesis may be supported by the 
observation that IGF stimulation affects ICM proliferation when treated from the cleavage stage 
(E2), but not the early blastocyst stage (E5). Further IGF1 treatment experiments and similar 
quantification of ICM proportions will be crucial to support these initial findings, as well as 
investigating whether the expression of additional lineage-associated genes are also affected, 
including human Epi-specific markers such as KLF17. 
 
A further point of contention is the intersection of lineage specifying genes with signalling 
networks during lineage establishment and maintenance in early development. This study finds 
that upregulating Gata6 in mouse ES cells enables FGF-independent upregulation of an ExEn 
gene program and cell fate conversion to iXEN cells, though previous mutant studies indicate 
that Gata6 and FGF likely converge to allow PrE specification in the mouse embryo. In future, 
mouse EpiSCs, which like the human Epi and ES cells depend on TGFβ/Nodal signalling (Brons 
et al. 2007; Tesar et al. 2007), would also represent an interesting system to further investigate the 
intersection of signalling networks and lineage-associated genes. Although FGF is routinely used 
to culture EpiSCs, the initial studies indicate that FGF-free support of EpiSCs is possible, as FGF 
mainly “improved the overall quality of the cultures, suggesting that it reinforces the efficiency of 
Activin signalling as in human ES cells” (Brons et al. 2007). Gata6 overexpression in EpiSCs, in 
the presence and absence of FGF, could therefore be a useful insight into the effect of ectopic 
Gata6 on pluripotency genes supported by Activin/Nodal signalling, with the added benefit that 
conditions for supporting mouse XEN cells are well defined, enabling an appropriate read out 
for conversion.  
 
Given that GATA6 overexpression also upregulates a similar ExEn network in human ES cells, 
albeit incompletely, how does this correlate with the differing role of FGF in the mouse and 
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human embryo? Perhaps an alternative signalling pathway is required to enhance GATA6 
function, and refining culture conditions to support putative human XEN cells could provide 
this. This however rests on the assumption that GATA6 plays a similar role in the human PrE 
specification hierarchy as it does in the mouse, which may not be the case given that GATA6 
exhibits a broader expression pattern in the human blastocyst and is present in the TE (Roode et 
al. 2012; Deglincerti et al. 2016). Intriguingly, TE-associated genes GATA3 and CDX2 were also 
upregulated following GATA6-induction in human ES cells, which may indicate a broader 
spectrum of GATA6 gene regulation, or simply be a by-product of pluripotency network 
downregulation. 
 
A similar broad expression pattern has been observed for GATA6 in primate (Boroviak et al. 
2015; Nakamura et al. 2016) and bovine embryos (Kuijk et al. 2012). However, this does not 
result in a consistent response to signalling, with GATA6 expression increased in response to 
FGF activation in bovine embryos but not completely ablated following inhibition (Kuijk et al. 
2012), suggesting more than one regulatory mechanism is in place. In marmoset embryos, 
inhibition of FGF or WNT reduces the proportion of GATA6-exclusive expression, but increases 
colocalisation between GATA6 and CDX2 or NANOG, suggesting the main effect is blurring of 
lineage assignations (Boroviak et al. 2015). Conversely, FGF inhibition in human embryos has no 
effect on GATA6 expression (Kuijk et al. 2012; Roode et al. 2012) and GATA6 was still detected 
in blastocysts following FGF treatment in the study presented here. Further experiments should 
aim to quantify the proportion of GATA6 cells in FGF-treated embryos, as well as explore any 
changes in co-localisation dynamics to determine the broader effect on lineage-associated gene 
expression in our investigations.  
 
It is clear that the human embryo represents an invaluable resource for study, and future 
comparisons with a variety of model organisms, especially with the increasing number of 
primate studies available, will no doubt vastly increase our understanding of the foundations of 
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early development. However, some challenges remain, such as availability of embryos donated to 
research, a relatively short time window for study, and difficulties with precision gene editing to 
investigate molecular hierarchy, although this latter point will likely shortly be overcome by 
CRISPR/Cas9 technology. Consequently, there remains a crucial requirement for an available 
stem cell population in vitro that is most reflective of the Epi counterpart in vivo. The 
demonstrable consistency in signalling requirements between mouse ES cells and the pre-
implantation Epi (Boroviak et al. 2014) allows mouse ES cells to be used as a suitable model to 
test regulatory mechanisms. However, as existing human ES cells are somewhat distinct from the 
Epi both in gene expression and signalling requirements, this presents difficulties, especially in 
exploring the basic biology of this developmental stage.  
 
It is likely that some of these issues can be overcome by using more suitable culture conditions. 
Several recent studies utilise a combination of inhibitors and growth factors in an attempt to 
generate human ES cells that are more similar to naïve mouse ES cells and the pluripotent cells of 
the human Epi (Chan et al. 2013; Gafni et al. 2013; Takashima et al. 2014; Theunissen et al. 2014; 
Valamehr et al. 2014; Ware et al. 2014; Guo et al. 2016). As discussed, some of these naïve cells 
successfully acquire characteristics of the human ICM, and as such will likely be a useful model 
for understanding the mechanisms involved in as global DNA hypomethylation or X-
inactivation, for example. However, the resulting cell lines remain somewhat divergent from the 
human Epi, although some do upregulate human Epi-specific factors such as KLF17 (Blakeley et 
al. 2015; Guo et al. 2016; Collier et al. 2017). Furthermore, a number of these conditions still rely 
on addition of exogenous FGF or on FGF-secreting MEF support layers, and utilise inhibitors 
uncovered in a mouse embryo context that target pathways that may not be relevant in the 
human. With this in mind, it would be interesting to determine if the signalling insights 
uncovered in the current work and the future experiments proposed, could eventually inform an 
embryo-centric culture system that would permit derivation of human ES cells that more 
accurately reflect the pluripotent Epi compartment. Ideally these cells would exhibit a number of 
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the criteria discussed here, such as Epi-specific gene expression patterns and epigenetic profiles 
as determined by transcriptomic and methylomic analyses. Further tests could investigate if 
improving the starting culture conditions resulted in a broader differentiation potential (in 
contrast to existing human ES cell lines which exhibit biases towards particular lineages in 
directed differentiation assays (Osafune et al. 2008)), or resulted in improved rates of iPS cell 
derivation. These two latter points would likely be useful from a clinical as well as basic research 
context. In parallel to this, further characterisation of the effects of modulating these signalling 
pathways with growth factors or inhibitors in vivo may shed light on downstream signalling 
effectors and their relationship to lineage-associated genes, Altogether, this work presents an 
outline aimed at broadening our current understanding of early mouse and human embryonic 
development. 
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